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ABSTRACT
Growth hormone (GH) deficiency is associated with impaired learning and
memory. One possible target for GH effects on memory is the hippocampus, a
brain region containing GH receptors (GHRs). To determine if GH acutely alters
hippocampal function, recombinant human GH (rhGH) was applied to in vitro rat
hippocampal brain slices. Extracellular recordings were used to assess effects of
GH on the field EPSP (fEPSP) and long-term potentiation (LTP) of the fEPSP.
GHR expression was measured in GH-treated and control rat hippocampal slices
using RT-PCR. The GH signaling pathway was investigated by studying the
effect of GH on the fEPSP after block of Janus kinase (JAK) by tyrphostin AG
490, phosphoinositide-3-kinase (PI3-kinase) by wortmanin, and mitogenactivated/extracellular response protein kinase kinase (MEK) by U0126. To
determine if protein synthesis is required, hippocampal slices were perfused with
cycloheximide, a protein synthesis inhibitor. I examined the effects of GH on
pharmacologically isolated N-methyl-D-aspartate receptor (NMDAR)-and αamino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor (AMPAR)-mediated
fEPSPs. Using western blotting, total and phosphorylated STAT5A/B, and
NMDAR subunits NR1, NR2A, and NR2B were measured in GH-treated and
control slices.
GH caused a gradual (2 hr) increase in fEPSP amplitude during
application that was maintained for more than 4 hours. Prior GH treatment (3hr)
prevented additional potentiation by tetanus (100Hz, 1s), indicating that similar
mechanisms contribute to both. GH caused equivalent enhancement of isolated
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NMDAR-fEPSPs and dual component fEPSP, indicating that GH effects are
mediated in part by NMDARs. GH enhancement of fEPSPs was blocked by
inhibitors of protein synthesis, JAK, PI3-kinase, and MEK, implicating all of these
signaling mechanisms in GH enhancement of synaptic transmission. In vitro GH
treatment of hippocampal brain slices for 15-30 min failed to alter either total or
phosphorylated STAT 5a/b. In vitro GH treatment of hippocampal brain slices
(3 hr) increased GHR mRNA, decreased NR2B protein, and increased
NR2A/NR2B ratio. My results clearly demonstrate a previously unknown role for
GH as a short-term modulator of hippocampal synaptic function.
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Neural growth hormone
Growth hormone (GH) is a polypeptide hormone formed of 191 amino
acids in a single chain (Corpas et al., 1993). It is secreted mainly by the
somatotropic cells of the anterior pituitary gland under the control of two main
factors secreted from the hypothalamus, GH releasing hormone (GHRH) and GH
inhibiting hormone or somatostatin (Corpas et al., 1993; Tannenbaum, 1990;
Vance et al., 1985; Reichlin, 1983). GH secretion is pulsatile (Wajnrajch, 2005;
Vance et al., 1985). GH secretion is increased during deep sleep ((Wajnrajch,
2005), by exercise (Berg and Bang, 2004), during starvation (Tanaka et al.,
2004). GH secretion is decreased during aging, and by obesity (Iranmanesh et
al., 1991).

Figure 1. Control of GH secretion. GH is secreted under the control of GHRH
and GH inhibiting hormone or somatostatin. GH secretion has a feed back
regulatory effect on the hypothalamus, inhibiting the secretion of GHRH and
increasing the secretion of somatostatin. The main stimuli increasing GH
secretion are deep sleep and exercise.
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Figure 2. Variations in human GH secretion throughout the day.
Major pulses of GH secretion occur in response to strenuous exercise
and deep sleep. The secretory profile for GH in rats is also pulsatile, ranging up
to several hundred ng/ml.
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It has recently become well established that GH gene expression is not
restricted to the pituitary gland but also occurs in many extra-pituitary tissues
including both the central and peripheral nervous system (Harvey and Hull,
2003). GH immunoreactivity is detected in the brains of human embryos at 8
weeks of development, before its appearance in the pituitary at the end of the
first trimester (Costa et al., 1993). On the tenth day of the 22 days gestational
period, GH starts to appear in rat brain: two days before its appearance in the
pituitary gland (Hojvat et al., 1982). GH is found in the midbrain, hippocampus,
cortex, striatum, olfactory bulb and cerebellum, at higher concentration in female
rats compared to male rats (Mustafa et al., 1994b). In the chicken high GH levels
are detected in the spinal cord as early as the second day of embryonic
development, before its appearance in the pituitary at mid-late incubation
(Harvey and Hull, 2003).

GH is present in hypothalamic as well as extra-hypothalamic areas of
chicken brain (Render et al., 1995). GH immunoreactivity has been detected in
the spinal cord, hippocampus, hypothalamus, otic and optic vesicles of chicken
embryonic brain (Murphy and Harvey, 2001). GH immunoreactivity has been
detected in the peripheral nervous system of chick embryos, particularly in the
trigeminal and vagal nerves (Murphy and Harvey, 2001). GH immunoreactivity
has also been detected in the hippocampus, periventricular, paraventricular,
inferior and infundibular hypothalamic nuclei, in the medial and lateral septal
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area, and in the median eminence of turkey brain and ringdove brain (Ramesh et
al., 2000).
Cerebrospinal GH could reflect either GH synthesized in the CNS or
sequestration of GH from systemic circulation (Harvey and Hull, 2003). In support
of the first hypothesis, trace amounts of GH have been detected in serum
following hypophysectomy (Lazarus and Scanes, 1988). Also the presence of
higher concentration of GH in the hypothalamic hypophyseal blood compared to
the peripheral blood indicates central secretion of GH into the systemic
circulation (Paradisi et al., 1993).

The abundance and wide spread presence of GHRs in the brain supports
the possibility that neural tissues are target sites for GH action (Harvey et al.,
1993). Hippocampal GHRs have been identified in both humans and rats (Lai et
al., 1993; Zhai et al., 1994). Recently the GHR cDNA nucleotide sequence has
been described in rat hippocampus (Thornwall et al., 2001).

Cerebrospinal fluid (CSF) levels of GH are much lower compared to that
of the systemic circulation, reflecting the poor permeability of cerebral
microvessels (Prahalada et al., 1999). Cerebrovascular permeability is greatest
during fetal development and decreases with age (Mustafa et al., 1995).
Increased cerebrovascular permeability after CNS injury leads to rapid
upregulation of GHRs in the endothelium of cerebral blood vessels (Scheepens
et al., 1999), suggesting the possibility of receptor mediated sequestration of GH
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from the systemic circulation (Harvey and Hull, 2003). GHRs are also abundant
in choroid plexus, supporting the peripheral origin of CSF GH (Harvey and Hull,
2003). CSF GH level is increased following its peripheral administration in
humans (Nyberg and Burman, 1996), with a dose-dependent increase in CSF
GH concentration in patients who received s.c. injections of GH (Burman et al.,
1996). Peripheral origin of central GH is also supported by the higher CSF level
of GH in patients suffering from acromegaly (Schaub et al., 1977). Additional
support for the peripheral origin of central GH is seen in the correlated decline in
CSF and plasma GH levels with age (Heinze et al., 1998).

Therapeutic applications of growth hormone
Growth hormone (GH) is considered a successful therapeutic drug for
children and adults with GH deficiency, as well as for growth retardation due to
chronic renal disease, Turner syndrome, and in children born small for
gestational age (Kappelgaard et al., 2004). Short children born small for
gestational age (SGA) have reduced serum leptin levels which are inversely
correlated with their chronological age (Boguszewski et al., 1997). Serum leptin
levels correlate with the growth response to GH treatment and may be used as a
marker for predicting the growth response to GH treatment (Boguszewski et al.,
1997). Hyperlipidemia, diabetes mellitus type 2, and coronary heart disease are
commonly associated with being born SGA (Pareren et al., 2003). GH treatment
has a positive effect for up to 6 years on body composition, blood pressure (BP),
and lipid metabolism (Sas et al., 2000). Therefore, GH treatment might
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counteract the reported higher risk of cardiovascular diseases in later life for
children born SGA (Sas et al., 2000).

It is well established that GH therapy has beneficial effects on statural
growth in children (Darendeliler et al., 2005). High dose GH therapy starting
before puberty accelerates bone age and induces an earlier onset of puberty
(Kamp et al., 2002). In short children born SGA, three years of GH treatment
normalized their height during childhood and increased bone maturation
proportionately to the height gain (Arends et al., 2003). Thus, it is better to start
GH treatment at an early age in order to achieve a normal height before puberty
starts (Arends et al., 2003). Serious GH deficiency and short stature can be
treated by KP-102 (D-alanyl-3-(2-naphthyl)-D-alanyl-L-alanyl-L-tryptophyl-Dphenylalanyl-L-lysinamide dihydrochloride, growth hormone-releasing peptide-2,
GHRP-2), which potently promotes growth hormone (GH) release by acting at
both hypothalamic and pituitary sites (Furuta et al., 2004). There are dosedependent increases in final height in children with idiopathic short stature
treated with GH (Wit et al., 2005).

One year of GH treatment in pre-pubertal children with idiopathic GH
deficiency (GHD), Turner syndrome (TS) or idiopathic short stature (ISS), and
short pre-pubertal children born SGA, normalized progression of bone age (BA)
(Darendeliler et al., 2005). GH treatment for three years induced proportionate
growth resulting in a normalization of height and other anthropometric
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measurements, including head circumference, in contrast to untreated SGA
control subjects (Arends et al., 2004). Lowered intelligence, poor academic
performance, low social competence, and behavioral problems are also
associated with being born SGA (Pareren et al., 2003). In adolescents born SGA,
GH therapy produced marked improvement over time in behavior and selfperception parallel to GH-induced catch-up growth (Pareren et al., 2004).

Prader-Willi syndrome (PWS) is a genetic disease that is caused by an
alteration in the molecular composition of a critical region of chromosome 15
(Whitman et al., 2002). PWS is characterized by obesity, hyperphagia, hypotonia,
short stature, hypogonadism, and a neurobehavioral profile that includes
cognitive deficits, learning problems, and behavioral difficulties that increase in
both quantity and severity over time (Whitman et al., 2002). In addition to
hyperphagia, which has proven refractory to all psychopharmocologic
intervention, decreased energy expenditure and reduced physical activity often
lead to morbid obesity in patients with PWS (Whitman et al., 2002). GH treatment
produced significant reduction of depressive symptoms and improvements in
physical parameters in children over 11 years old with PWS (Whitman et al.,
2002).

Human growth hormone has become a popular ergogenic aid, improving
exercise performance among athletes (Stacy et al., 2004). GH has
supraphysiologic effects leading to lipolysis, with increased muscle volume
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(Stacy et al., 2004). In addition, GH is considered an anti-aging drug and has
improved athletic performance in isolated studies (reviewed in Stacy et al., 2004).

Both recombinant human growth hormone (rhGH) and insulin-like growth
factor-I (IGF-I), have been considered beneficial for diseases associated with
increased catabolism such as acquired immune deficiency syndrome (AIDS)
(Laurence, 1995). It has now been confirmed that GH as well as IGF-I produce
increases in body weight, lean body mass, and sense of well-being among HIV+
individuals because of their ability to promote nitrogen retention, protein
synthesis, and lipolysis (Laurence, 1995). GH also augments cellular immune
function and modulates T lymphocyte trafficking in animal models of immune
suppression, suggesting benefit for any immune suppressive disorders, including
HIV infection (Laurence, 1995).

Growth hormone and memory function
Recent studies have shown that GH affects many functions of the central
nervous system, with beneficial effects on memory, alertness and motivation
(Fargo et al., 2002). GH deficiency (GHD) has well known detrimental effects on
cognition and memory in humans. General fatigue, lack of concentration,
memory disabilities and a diminished subjective sense of wellbeing are all
problems detected in untreated adult GHD patients (Bjork et al., 1989; McGauley
et al., 1990). Sleep disturbances and psychologically immaturity are problems of
young GHD patients (Hayashi et al., 1992). Animal studies support these human
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observations. In a passive avoidance task in young rats (3 months old), GH
administration facilitated long-term memory and delayed extinction (SchneiderRivas et al., 1995). In this study, old rats (24 months old) did not benefit from GH
treatment. However, in other studies using a different learning task, the Morris
water maze, learning in old rats was improved by treatment with GHRH
(Thornton et al., 2000) or GH itself (Ramsey et al., 2004).

Long Term Potentiation (LTP) is a Model System for Mechanisms of
Memory
Physiologically, memories are caused by changes in the strength of
synaptic transmission between neurons resulting in the formation of new
pathways or facilitated pathways for transmission of nerve signals following
previous neural activity (Guyton and Hall, 2000). Long term potentiation (LTP) is
a long-lasting increase in the strength of synaptic transmission between nerve
cells, induced in response to high frequency afferent stimulation (Bliss and Lomo,
1973). LTP has been most extensively studied in the hippocampus, a brain
region known to be involved in memory functions (Bliss and Collingridge, 1993).
LTP is considered the best available model for studying the synaptic
modifications that underlie memory formation and storage (Bliss and
Collingridge, 1993), and for this reason interest in LTP has steadily increased.

A novel form of synaptic plasticity, homosynaptic long-term depression
(LTD), has also recently been documented. LTD, like LTP, requires Ca2+ entry
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through NMDARs (Bear and Malenka, 1994). Recent studies suggest that LTD
and LTP are functionally inverse processes, and that the mechanisms of LTP
and LTD may converge at the level of specific phosphoproteins (Bear and
Malenka, 1994). Although the induction of both LTD and LTP require Ca2+ influx,
a stronger depolarization and a greater increase in [Ca2+]i are required to induce
LTP than to initiate LTD (Artola and Singer, 1993).

Glutamate receptors (GluRs)
Glutamate is the major excitatory neurotransmitter in the central nervous
system, and GluRs are widely expressed throughout all major division of the
central nervous system (McBain and Mayer, 1994). Ionotropic GluRs are
classified into three major classes: alpha-amino-3-hydroxy-5-methyl-4-isoxazole
proprionate (AMPA), kainate and N-methyl-D-aspartate (NMDA), based on their
electrophysiological and pharmacological properties (McBain and Mayer, 1994).
Although the first recognized glutamate receptors were ligand-gated ion
channels, a large number of G protein-coupled GluRs are also expressed
throughout the CNS (Nakanishi, 1992).

N-methyl-D-aspartate receptors (NMDARs) are selectively activated by
NMDA, a synthetic analogue of aspartic acid, which does not occur naturally in
the brain (Watkins and Evans, 1981). The NMDAR response to NMDA is potently
blocked by aminophosphovalerate (AP5) (McBain and Mayer, 1994). Responses
at NMDARs are strongly voltage-dependent and show high Ca2+ permeability
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(McBain and Mayer, 1994). The AMPA/ kainate subtypes of GluRs are also
ligand-gated ion channels for which AMPA and kainate act, respectively, as
preferential agonists. Both AMPA and kainate responses are blocked by a
related set of quinoxaline diones (CNQX, DNQX, NBQX), but not by AP5
(McBain and Mayer, 1994). Non NMDARs (AMPA and kainate receptors) in
general have only weak voltage dependence and low Ca2+ permeability (McBain
and Mayer, 1994).

Four genes (GluR A-D/GluR1-4) code for the AMPA glutamate receptor
subunits (Schoepfer et al., 1994). NMDARs are formed by coexpression of the
NR1 and one or more members of the NR2 family (NR2A-D) of genes (Schoepfer
et al., 1994). The NR1 subunit is expressed throughout the brain and serves as a
general partner for association with NR2 subunits (Monyer et al., 1992). The
kinetic and pharmacological properties of NMDARs are dependent on the
specific NR2 subunit expressed (Schoepfer et al., 1994).

GluRs, LTP, and memory
GH affects expression of NMDARs, which are required for normal memory
function (Le Greves et al., 2002). Insertion of new GluRs into the postsynaptic
membrane (Nayak et al., 1998; Shi et al., 1999) and the phosphorylation of the
existing GluRs (Soderling and Derkach, 2000) are putative mechanisms
underlying memory formation. NMDARs have an important role in synaptic
plasticity, synaptogenesis, and excitotoxicity (Mallon et al., 2004). In cultured
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neurons, insertion of GluR1-containing AMPARs into neuron membranes was
induced by NMDAR activation, highlighting the role of NMDARs in synaptic
plasticity (Passafaro et al., 2001).

These findings demonstrate a mechanistic long-term relationship between
GH, memory function, NMDARs and LTP. Although the beneficial therapeutic
effects of GH on memory and cognition are well known, the underlying synaptic
mechanisms and their relation to GluRs in general and NMDARs in particular, as
well as the GH signaling pathway, have not been well investigated in the
hippocampus, or for that matter, any other brain region. The purpose of my
dissertation is to investigate possible short term effects of GH on synaptic
transmission in the CA1 area of rat hippocampus, and the mechanisms
underlying those effects. In assessing the potential role of GH as a short-term
regulator of hippocampal function, I addressed three related questions.
First, does GH alter synaptic function in hippocampal area CA1, and if so, how?
To answer this question I applied GH to rat hippocampal brain slices and
examined excitatory synaptic transmission for any GH-induced changes. A
paired-pulse stimulation protocol was used to determine whether any change in
synaptic strength was accompanied by an alteration in the presynaptic release of
glutamate. I also examined the effect of brief tetanization (100 Hz, 1 s) following
3 hr of GH pretreatment, to determine if both GH and brief tetanus act through
common mechamisms to regulate hippocampal synaptic transmission. The first
section of my dissertation includes these experiments.
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Second, what signaling pathway(s) are responsible for short-term effects of GH
on hippocampal synaptic function, and is synthesis of new proteins required for
these effects? I hypothesized that GHR signaling in hippocampus would use
signaling pathways previously described in other tissues. This hypothesis was
tested by examining the effects of pharmacological inhibition of specific
components of the hypothesized hippocampal GHR signaling pathway. These
experiments form the basis of the second section of my dissertation.
Third, I asked whether GH effects on hippocampal synaptic function are
mediated by NMDARs or AMPARs. I also asked if short-term treatment with GH
has similar consequences on NMDAR expression as long-term, chronic
treatment with GH. To answer the first of these questions, I used specific
neurotransmitter receptor antagonists to pharmacologically isolate NMDAR and
AMPAR components of synaptic transmission, tested GH for effect on these
isolated, components and compared the isolated NMDAR-mediated fEPSPs
(fEPSPNs) and isolated AMPAR-mediated fEPSPs (fEPSPAs) to the dual
component fEPSPs. To answer the second question I used western blotting to
measure NMDA-NR1, NR2A, and NR2B expression levels in GH treated and
control rat hippocampal slices. The third section of my dissertation contains the
results of these experiments.

14
14

Section I
GH Enhances Excitatory Synaptic Transmission in Area CA1 of
Rat Hippocampus
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Introduction

Growth hormone and cognitive function
Age-related reductions in growth hormone secretion and cognitive
impairments associated with aging are well documented. Carlson et al. (1972)
reported a loss of nocturnal surges of GH in elderly individuals.

In adult hypopituitary patients with GH deficiency, rhGH treatment for 3
months had a beneficial effect on attentional performance (Oertel et al., 2004).
The P300 event-related potential (ERP) is a positive deflection in the EEG which
occurs with a 300 ms latency following a novel or surprising event. The P300
ERP is thought to reflect cognitive and memory processing in frontal and
temporal lobes, and it is altered in neurological patients with various cognitive
impairments (Golgeli et al., 2004). P300 ERP latencies were prolonged in GHD
patients with Sheehan's syndrome, indicating cognitive impairment. Six months
of GH replacement therapy (GHRT) significantly elevated serum IGF-I levels, and
improved P300 latencies, indicating normalization of cognitive function by GHRT
(Golgeli et al., 2004).

Aging is associated with both declining activity of the growth hormoneinsulin-like growth factor-I (GH-IGF-I) axis and with a decrease in cognitive
function (Arwert et al., 2003). An oral mixture of glycine, glutamine and niacin
can enhance GH secretion and improve mood and cognition in healthy middle-
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aged and elderly subjects (Arwert et al., 2003). In a two year study, Stouthart et
al (2003) examined psychological and cognitive consequences of discontinuation
and restoration of GH treatment in young adults with childhood-onset growth
hormone deficiency. Discontinuation of GH treatment led to a decrease in quality
of life (QoL) within 6 months, and this effect was counteracted within 6 months
after restarting GH treatment (Stouthart et al., 2003). A significant decrease in
IGF-I level and an increase in the number of psychological complaints and
depression were observed in the first 6 months of the GH discontinuation period
(Stouthart et al., 2003). Increased IGF-I level, decreased anxiety and improved
QoL were observed in the first 6 months of GH restoration (Stouthart et al.,
2003). Depression scores tended to decrease across the 12 month treatment
period. The intra-subject IGF-I level was negatively correlated with depression,
fatigue, tension and anxiety, and was positively correlated with vigor and memory
during the 2-year discontinuation and treatment period (Stouthart et al., 2003).

Both GH and IGF-1 affect the hippocampus. Hippocampal IGF-1 mRNA
levels were increased by 1 week of treatment with either GH or GH-releasing
peptide-6 (Fargo et al., 2002). The same effect was seen in the hypothalamus
and cerebellum, but not the cerebral cortex (Fargo et al., 2002). Trace
conditioning, a variant of Pavlovian conditioning, requires a learned association
between two stimuli that are discontiguous in time, and the correct differentiation
between the interstimulus interval, which is stable, and the intertrial interval,
which is variable. Hippocampal GH mRNA, assessed by microarray, real-time
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PCR and in situ hybridization, was dramatically up-regulated following 200 trials
of trace conditioning (Donahue et al., 2002). In addition, somatostatin mRNA
which encodes a direct antagonist of GH secretion was reduced during trace
conditioning (Donahue et al., 2002).

Lemon et al. (2003) examined learning on an 8 arm radial maze in
transgenic mice which over-expressed growth hormone (TGM). TGM had
elevated and progressively increasing free radicals (reactive oxygen and nitrogen
species) in brain that strongly correlated with reduced survivorship. Compared to
controls, TGM mice showed enhanced learning during early adulthood, but
accelerated decline of learning during aging. The cognitive decline of TGM was
abolished by a complex "anti-aging" dietary supplement formulated to promote
membrane and mitochondrial integrity, increase insulin sensitivity, reduce free
radicals, and ameliorate inflammation.

Long Term Potentiation (LTP) is a Model System for Mechanisms of
Memory
Long term potentiation (LTP), a long lasting enhancement of synaptic
transmission in response to high frequency stimulation (HFS) (Bliss and Lomo,
1973), represents a good model for studying the synaptic modifications that
underlie memory formation and storage (Bliss and Collingridge, 1993). In the
CA1 area of the hippocampus, LTP is triggered by calcium influx into
postsynaptic neurons. NMDARs are a major route for this calcium entry (Bliss
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and Collingridge, 1993). Under some circumstances, metabotropic GluRs and
voltage-gated calcium channels also contribute to postsynaptic calcium increase.
The postsynaptic Ca2+ signal triggering LTP is transient; sustained enhancement
of synaptic transmission depends on Ca2+-activated, postsynaptic signaling
pathways. These pathways lead to the insertion of new GluRs into the
postsynaptic membrane (Nayak et al., 1998; Shi et al., 1999) and the
phosphorylation of existing GluRs (Soderling and Derkach, 2000). Enhanced
glutamate release from the presynaptic terminals also contributes to the
maintenance of LTP (Bekkers and Stevens. 1990; Schulz et al., 1994; Kullman et
al., 1996). These mechanisms support LTP during the first few hours Longer
lasting synaptic enhancement requires gene expression and synthesis of new
proteins (Stanton and Sarvey, 1984; Huang and Kandel, 1994; Nguyen et al.,
1994; Frey et al., 1996), and is accompanied by structural alterations of the
synapse (Desmond and Levy, 1988; Trommald et al., 1996; Toni et al., 1999).

The use of LTP as a model for studying memory is supported by the
importance of hippocampus in memory (Squire and Zola-Morgan, 1992). In
addition, behavioral experiments in animals have shown that pharmacological
and genetic manipulations which prevent normal NMDAR function cause parallel
disruption of LTP and memory (Morris et al., 1986; Davis et al., 1992; Tsien et
al., 1996). Although most experiments have been conducted on rats, mice and
nonhuman primates, normal human memory performance is also dependent on
hippocampal NMDARs (Grunwald et al., 1999). In addition to NMDARs, other
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components of the signaling pathways responsible for LTP have been implicated
in learning and memory, including metabotropic GluRs (Riedel et al., 1994; Kaba
et al., 1994) and protein kinases (Mathis et al., 1992; Silva et al 1992). These
findings demonstrate that a common set of cellular mechanisms underlies both
LTP and memory.

The purpose of this study was to determine if short-term treatment with
GH would alter synaptic transmission in the CA1 area of rat hippocampus. To
achieve this goal, I examined the effects of GH application on excitatory synaptic
transmission and on paired-pulse facilitation of excitatory synaptic transmission
(a presynaptic, very short-duration form of plasticity). In addition I examined the
effect of brief high frequency stimulation (HFS, 100 Hz, 1 s) following 3 hr of GH
pretreatment, to determine if both LTP and GH act through common regulatory
mechanisms. Electrophysiological recordings from area CA1 of rat hippocampal
brain slices were used in these experiments.
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Materials and Methods

Slice preparation
Hippocampal slices were prepared from 1.5 to 3 month old male SpragueDawley rats (Hilltop Laboratory Animals). Animals were sedated by inhalation of
a CO2/air mixture and decapitated. The skull was opened and the brain was
removed and submerged in chilled, oxygenated (95% O2/5% CO2), low Ca2+/high
Mg2+ artificial cerebrospinal fluid (ACSF), pH 7.35 and composed of: 124 mM
NaCl, 26 mM NaHCO3, 1.2 mM NaH2Po4, 3 mM KCl, 0.5 mM CaCl2, 5 mM
MgSO4 and 10 mM glucose.

While submerged in chilled low Ca2+/high Mg2+ ACSF the brain was
trimmed to a block containing both hippocampi. The block was glued to the
stage of a vibrating microtome (Campden Instruments), immersed in a bath of
chilled, oxygenated, low Ca2+/high Mg2+ ACSF, and 400 µm coronal sections
were cut. Sections containing the hippocampus in transverse profile were
selected and transferred to a small petri dish, where they were further dissected
to free the hippocampus from surrounding tissue (Figure 3). After dissection,
hippocampal slices were transferred to a holding chamber, where they were
stored for later use (Figure 4).
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Figure 3. Preparation of rat hippocampal slices. Rat brains were blocked and
glued to the stage of a microtome (top, left to right). Sections were cut, collected
and dissected to isolate individual hippocamal slices (bottom, left to right).

Slices were maintained in a holding chamber at room temperature (20-22
ºC) at the ACSF/atmosphere (95% O2/5% CO2) interface. The holding chamber
was filled with standard ACSF, pH 7.35 and composed of 124mM NaCl, 26mM
NaHCO3, 3.4 mM KCl, 1.2 mM NaH2PO4, 2.0 mM CaCl2, 2.0 mM MgSO4, and 10
mM glucose. Slices were incubated in the holding chamber for a minimum of
one hr prior to use.
22
22

Figure 4. The interface holding chamber used for preincubation of
individual hippocampal brain slices. The chamber was composed of a small
glass beaker with nylon netting stretched over the opening and covered with a
piece of lancet paper. The small beaker was placed inside larger beaker and
both beakers were filled with ACSF up to a level matching the height of the
smaller beaker. A line supplying a gas mixture (95% O2/ 5% CO2) was placed
inside the holding chamber. The chamber was covered and kept at room
tempreture. Hippocampal slices were incubated for at least an hour before being
transferred to the recording chamber.
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Slices were withdrawn from the holding chamber as needed and placed in
a low volume (approximately 200 µl) interface recording chamber, where they
were continuously perfused at a rate of 1-1.5 ml/min with standard ACSF. The
recording chamber was kept at a temperature of 25±0.5 °C. A minimum 30 min
period was allowed for recovery after transferring slices from the holding to the
recording chamber.

Field potential recording
Extracellular potentials were recorded through low impedance (3-4 MΩ)
glass micropipettes filled with ACSF and placed into the stratum radiatum of area
CA1 (Figure 5 and 6). Signals were amplified (gain 1000) and filtered (0.1 3,000 Hz) using a WPI DAM50 amplifier, then digitized (10 kHz; National
Instruments) and stored on a personal computer.

Synaptic stimulation
Postsynaptic potentials were evoked by delivery of constant voltage
stimuli through a bipolar stimulating electrode placed into stratum radiatum.
Stimuli were delivered at a 15 sec interval. In some field potential recordings,
paired stimuli (50 ms interstimulus interval) were delivered in order to measure
paired-pulse facilitation. Paired-pulse facilitation was quantified as the ratio of
the second response divided by first response.
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Postsynaptic potentials evoked in standard ACSF were quantified by
measuring the slope of the linear portion of the initial response. Changes in
synaptic response caused by GH treatment or LTP induction were expressed as
percentage of baseline prior to treatment or tetanization.

Figure 5. The recording chamber (left) and typical placement of recording
and stimulating electrodes (right). The recording chamber used in the study
was Stoelting company model 51430 tissue chamber (left). A bipolar metal
stimulating electrode and a glass recording electrode were placed into
hippocampal area CA1.
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Figure 6. Schematic illustration of hippocampal synaptic organization.
Transverse section of rat hippocampus showing the three major afferent
pathways that form the trisynaptic circuit in hippocampus and the typical
placement of recording and stimulating electrodes in stratum radiatum of area
CA1. The arrows indicate the direction of information flow through the trisynaptic
circuit.
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LTP induction
LTP was examined in standard ACSF. LTP was induced by a single high
frequency stimulus train (100 Hz, 1 s). The stimulus intensity used for tetanic
stimulation was set at the population spike threshold. LTP was assessed in
slices pretreated with GH (22 ng/ml, dissolved in standard ACSF) for 3 hr and in
control slices exposed to standard ACSF only for an equivalent time period.
Slices were pretreated in the interface holding chamber, then transferred to the
recording chamber where they were perfused with standard ACSF for recording
and assessment of LTP.

Reagents
I used rhGH (Bachem). The doses used in these recordings ranged from
0.5 to 1 nM or (11-22 ng/ml) which is within the physiological range; GH serum
level ranged between few ng/ml and several hundred ng/ml in rats (Kimura and
Tsai 1984; Everson and Crowley, 2004). Human GH is a potent, relatively
selective agonist of GHRs in male rats. Mustafa et al. (1994a) reported the
presence of specific binding sites for hGH in rat brain which were moderately
high in hippocampus, hypothalamus and striatum. Moreover, those binding sites
for hGH were almost exclusively somatogenic in male rat brains (Mustafa et al.,
1994b). However in female rat brain these sites display somatogenic and
lactogenic characteristics (Mustafa et al., 1994b). This is also supported by the
finding of Ranke et al. (1973) who studied the sex differences in binding of hGH
to isolated rat hepatocytes. They reported that hGH binds only to somatogenic
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receptor in hepatocytes of male rats. However in female rats and estrogen
treated males hGH has both somatogenic and lactogenic properties (Ranke et
al., 1973). In summary, in male rats (used in this study) hGH has less potential to
bind non specifically to lactogenic receptors.

Data analysis
Field potentials were collected and analyzed using The WinWCP program
(John Dempster, University of Strathclyde). Additional analysis was completed
using Excel (Microsoft) and Origin (OriginLab). All statistics are presented as
mean ± one standard error of the mean. Statistical significance was assessed
using paired and unpaired t-test, as appropriate, with p<0.05 considered
significant.
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Results

Growth hormone enhanced excitatory synaptic transmission
I used field potential recordings (fEPSP) to determine if GH application
affects excitatory synaptic transmission. Application of GH (11-22 ng/ml) caused
a slow increase in fEPSP slope (Figure 7). Although fEPSPs began to increase
within minutes of starting GH application, the maximal increase required 60-120
min. GH enhancement of fEPSP persisted for more than 4 hours Control slices,
exposed to ACSF for the same duration, did not show any increase in fEPSP
slope (p<0.01, control vs GH after 60 min of application).

Growth hormone did not affect paired pulse facilitation
The GH-induced increase in fEPSP slope could be due to enhanced
postsynaptic response to glutamate, or increased presynaptic release of
glutamate. Increased probability of transmitter release is accompanied by
decreased paired-pulse facilitation (PPF) (Dobrunz and Stevens, 1997).
Therefore, to determine if increased probability of glutamate release might
underlie the GH enhancement, I examined PPF during GH application. Neither
GH treated nor control slices showed a change in PPF ratio (Figure 8). This lack
of change in PPF argues against an increase in glutamate release as a
mechanism for the GH enhancement of excitatory synaptic transmission.
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Growth hormone inhibits LTP in area CA1 of rat hippocampus
A single train of high frequency stimuli (HFS, 100 Hz, 1 s) failed to
potentiate synaptic responses in slices pretreated with GH (22 ng/ml; p > 0.4).
However, HFS with the same 100 Hz protocol caused significant enhancement of
fEPSPs in control slices pretreated with standard ACSF (p < 0.02; Figure 9).
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Figure 7.
A
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Figure 7. GH Enhanced Excitatory Synaptic Transmission in Area CA1 of
Rat Hippocampus.
A. GH application (11-22 ng/ml) caused a slow enhancement of fEPSPs
(squares) in comparison to control slices treated with ACSF only (diamonds). GH
application began after 15 min of recording and continued for >5 hours The inset
at top shows fEPSPs changes during the baseline and after 3 hr of GH and
control treatment.
B. Summary of GH effects on fEPSPs. fEPSPs were averaged over 15 min
baseline period and 1 hr period during GH application. fEPSPs from GH treated
slices were significantly enhanced compared to controls at all time points:
*P<0.05, **P<0.01, ***P<0.005. These data represent the average of 10 slices
treated with GH and 4 control slices.
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Figure 8.
A
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Figure 8. GH did not alter the paired-pulse facilitation (PPF) ratio.
A. Paired stimuli (50 ms interstimulus interval) were delivered at 15 sec intervals.
There was no change in PPF ratio during GH application. The inset at top shows
fEPSPs during baseline and the second hr of GH application. Substantial pairedpulse facilitation is seen at all times (the second response is bigger than the first
response), but the application of GH did not alter the PPF ratio.
B. Summary of all recordings in which PPF was examined during GH
application. PPF was not significantly different during either the first or the
second hr of GH treatment compared to the baseline (p < 0.2, n = 9)
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Figure 9.
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Figure 9. GH pretreatment prevented LTP in area CA1 of rat hippocampus.
A. Stable baseline responses were recoded for a 15 min period preceding tetanic
stimulation (100 Hz 1s). Control slices showed enhancement of fEPSPs after
tetanus (diamonds), but LTP was completely prevented in GH pretreated slices
(squares). The inset at top shows baseline responses and responses after
tetanus (control upper left and GH treated upper right).
B. Summary of LTP results in GH pretreated and control slices. Control slices (n
= 8) showed significant potentiation of the fEPSP (*p<0.02), but GH pretreated
slices (n=8) failed to show any significant change in fEPSP (ns p<0.44).
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Discussion

Short term, minutes to hours, application of GH to in vitro rat hippocampal
brain slices enhanced excitatory synaptic transmission and also inhibited further
potentiation by tetanus. In a recent study Fargo et al. (2002) have shown that GH
affects many functions of the central nervous system, with beneficial effects on
memory, alertness and motivation. Le Greves et al. (2002) observed dose
dependent improvement in memory and learning after 1 week of daily injections
of rhGH in hypophysectomized male rats. Memory deficiency including both short
and long term memory is a well known syndrome in GHD patients (Deijen et al.,
1996; Aleman et al., 2000). In addition, adult patients suffering from
hypopituitarism with GH deficiency showed improvement of attentional
performance when treated with GH for at least 3 months (Oertel et al., 2004). An
age-related decrease of GH is associated with defects in spatial memory in
animals (van Dam et al., 2000), and it is well established that the decline in the
cognitive function with aging is paralleled with decreased circulating levels of GH
(Le Greves et al., 2002).

This raises the question, how does GH treatment improve memory,
alertness, and cognition? The process of memory storage in the brain certainly
involves some form of synaptic modification (Rosenzwing and Barnes, 2003).
Recent investigations have suggested a role for GH in memory, which may be
mediated by the influence of GH on neuronal plasticity in the hippocampus. Since
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the hippocampus is critically important in memory and learning processes (Le
Greves et al., 2002), I applied GH to in vitro hippocampal brain slices of rats to
determine if it affects synaptic transmission. GH substantially enhanced synaptic
transmission in area CA1 of rat hippocampal slices, exerting a maximum effect
within 2 hr (Figure 7). Taken together, this suggests that GH may improve
memory by enhancement of synaptic transmission between hippocampal
neurons. However, prior treatment with GH for 3 hr also blocked synaptic
enhancement induced by brief tetanus (100 Hz, 1 s), (Figure 9). How can this
dual effect of GH be explained?

Although LTP was originally described as synaptic enhancement resulting
from high frequency electrical stimulation (Bliss and Collingridge, 1993), similar
synaptic potentiaton may result from application of several different chemical
compounds, including neutrophins, second messenger analogs, and
conventional neurotransmitters. Although the term LTP typically refers to
electrically-induced synaptic enhancement, we could say that LTP is of 2 types:
drug-induced and electrically-induced. Drug-induced LTP has been
demonstrated following treatment with the neurotrophins, BDNF and NT-3,
forskolin and the membrane-permeable cAMP analog Sp-cAMPS, and also
dopamine receptor agonists (D1 and D2) (Frey et al., 1993; Huang et al., 1994.,
Huang and Kandel, 1995; Kang and Schuman, 1995).
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Previous studies in hippocampal slice preparations have distinguished two
major temporal phases of LTP, early and late, based on their sensitivities to
inhibitors of mRNA and protein synthesis (Krug et al., 1984; Huang and Kandel,
1994). In contrast to the early phase of LTP (E-LTP), the late phase of LTP (LLTP) is of greater amplitude and longer duration, lasting more than 3 hr (Kelleher
et al., 2004a). In contrast to the L-LTP produced by repeated tetanization, L-LTP
produced by drugs develops gradually, requiring 1 to 2 hr to reach its maximal
level. Both drug- and electrically-induced L-LTP are abolished completely by
protein synthesis inhibitors (Kelleher et al., 2004a). Previous studies indicated
that L-LTP produced by repeated tetanization and L-LTP produced by elevation
of intracellular cAMP share a common protein synthesis-dependent mechanism
(Kelleher et al., 2004a). Establishment of cAMP-induced LTP prior to repeated
tetanization blocks L-LTP (Frey et al., 1993; Huang and Kandel, 1994). The idea
that drug-induced L-LTP can block electrically-induced L-LTP is also supported
by the finding of Martin et al. (1997) that MAPK may be a general mechanism for
long-term plasticity in all kinds of LTP. They found that MAPK translocates into
the nucleus of the presynaptic but not the postsynaptic cell during 5-HT-induced
long-term facilitation, suggesting that MAPK may play a similar role in
hippocampal long-term potentiation. PKCζ may also play essential roles in both
drug-induced and electrically-induced LTP, since treatment of hippocampal CA1
pyramidal neurons with PKC ζ activators produces robust potentiation of synaptic
transmission that occludes subsequent electrically-induced LTP (Ling et al.,
2002).
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I found that a brief tetanus (100 Hz, 1 s), which normally induces LTP had
no effect in slices pretreated with GH for 3 hours This effect of GH on
hippocampal synaptic function raises another question; does GH act through a
similar signaling pathway to that of LTP? If so, then prior saturation of this
pathway by pretreatment with GH should prevent subsequent electrically-induced
LTP. In order to answer the questions raised by my first set of experiments, the
GH signaling pathway in hippocampus must first be defined. It will then be
possible to compare the GH signaling pathway with the LTP signaling pathway
which is already well described in the literature.
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Section II

Growth Hormone Signaling Pathways in Area CA1 of Rat
Hippocampus
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Introduction

Pretreatment with GH blocked the effect of a brief tetanus (100 Hz, 1 s)
which normally induces LTP. This effect of GH on hippocampal synaptic function
raises another question; does GH act through a similar signaling pathway to that
of LTP? If so, then prior saturation of this pathway by pretreatment with GH
should prevent subsequent electrically-induced LTP. In order to answer this
question tetanization-induced-LTP signaling pathway(s) and GH signaling
pathway(s) in other tisssues which are already well described in the experimental
literature will be reviewed.

Tetanization-induced L-LTP signaling pathway
LTP induction is disrupted by pharmacological inhibitors of the Ras
effectors PI3-kinase (Kelly and Lynch, 2000; Lin et al., 2001; Kelleher et al.,
2004a; Sanna et al., 2002) and p44/42 MAPK (Sweatt, 2001; Adams and Sweatt,
2002). LTP is also inhibited in hippocampal pyramidal cells expressing a
dominant negative form of Ras (Zhu et al., 2002). Furthermore, MEK inhibitors
strongly reduce the induction of LTP by theta pulse stimulation (TPS) (Winder et
al., 1999; Watabe et al., 2000). There are at least two possible roles for ERK
activation in LTP. First, MAPK activation has an important role in the mRNA and
protein synthesis stages of LTP maintenance (Impey et al., 1998; Davis et al.,
2000). Second, MAPK activation contributes to LTP induction through
downregulation of dendritic A-type K+ channels (Sweatt, 2001). Downregulation
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of dendritic A-channels allows greater postsynaptic depolarization during
tetanization, leading to greater voltage-dependent calcium influx, and enhanced
downstream activation of calcium-dependent processes.

LTP induced by short trains of TPS is almost completely blocked by the
PI3-kinase inhibitors LY294002 and wortmannin (Opazo et al., 2003). PI3-kinase
is important for the induction of LTP, but not for the maintenance of LTP, as PI3kinase inhibitors applied after LTP induction do not block LTP (Opazo et al.,
2003). Several possible roles for PI3-kinase in LTP induction have been
suggested. LTP-inducing patterns of synaptic stimulation activate the atypical
PKC isoform PKCζ (Sacktor et al., 1993), and inhibitors of PKCζ inhibit LTP in
hippocampal area CA1 (Ling et al., 2002). PI3-kinase contributes to the early
activation of PKCζ during LTP induction (Opazo et al., 2003), perhaps via
activation of PDK-1 (Chou et al., 1998; Le Good et al., 1998). In addition, PI3kinase is important for the trafficking and insertion of some membrane proteins
during LTP induction (Corvera and Czech, 1998; Wu et al., 1998; Rameh and
Cantly, 1999; Lhuillier and Dryer, 2002). Finally, PI3-kinase might have a role in
the dendritic spine changes associated with LTP and induced by either
organizational changes of actin cytoskeleton (Rodgers and Theibert, 2002) or
activation of synaptic NMDA receptors (Yuste and Bonhoeffer, 2001).
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Growth hormone signaling pathway
Tissue sensitivity to GH. Growth hormone (GH) differs from other
pituitary hormones in its wide spectrum of cellular activities in several different
tissues which are all mediated by a common receptor, suggesting tissue-specific
differences in the post-receptor mechanisms (Hull and Harvey, 1998). One of the
mechanisms that confers specificity is tissue sensitivity to GH stimulation. Tissue
sensitivity depends upon the abundance of GH receptors (GHRs), the amplitude
and pulsatility of GH secretion and the presence of non-signal transducing GHbinding proteins (GHBPs), which result from alternate splicing of GHR gene
transcripts (Hull and Harvey, 1998). Additional diversity stems from tissuespecific autoregulation of GHRs and GHBPs. Hypophysectomy decreased both
GHR and GHBP transcripts in the hypothalamus of rats by 20%; however,
neither transcript was affected in the liver, spleen, cortex/neocortex or brainstem
(Hull and Harvey, 1998). On the other hand, a single bolus GH injection
increased circulating GH concentrations, GHR and GHBP mRNA content by 2530 % in all brain regions and in the spleen of hypophysectomized rats (Hull and
Harvey, 1998).

GH regulation of GHRs. GHR mRNA levels were increased within 1 hr
of a single injection of human GH (100 µg/ rat), and maximal levels were reached
between 3-12 hr after the injection (Vikman et al., 1991). The increase in GHR
mRNA levels was dose dependent and also was observed after prolonged
treatment (1 or 5 mg/kg/day for 6 days) with bovine GH. Furthermore, there was
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a rapid and GH-dependent regulation of GHR mRNA levels in adipose tissue
(Vikman et al., 1991). Using PCR, GH treatment by s.c. injection for 10 days
increased expression of GHR transcripts in the hippocampus of young adult rats,
reflecting the ability of the hormone to reach the brain and stimulate hippocampal
cells (Le Greves et al., 2002).

Overview of GHR signaling. The receptors for GH, prolactin,
erythropoietin, and interleukin 2 all belong to the same large family of single
chain transmembrane receptors (Xiaowei et al., 1995), the cytokine receptor
superfamily. The receptors in this family have similar extracellular domains which
are rich in cysteine, a motif that has been shown to be important in proteinprotein interaction as well as in cell-cell interaction (Bazan, 1989; Patty, 1990).
Activation of the GHR, like other members of the cytokine receptor family,
stimulates Janus kinase 2 (JAK2) association with the GHR, followed by tyrosine
phosphorylation of both proteins (Argetsinger et al., 1993; Sotiropoulos et al.,
1994). The activated GHR-JAK2 couple stimulates several signaling cascade,
including the Ras/Raf/MEK1/MAPK pathway, the insulin receptor substrate1(IRS-1)/PI3kinase pathway and the STAT pathway (Liang et al., 2000).

MAPK pathway. Binding of GH and prolactin (PRL) to their receptors
activates JAK2 tyrosine kinase, the initial step in all biological actions of GH
(Yamauchi et al., 1998). The activated GH/JAK2 complex in turn activates STATs
as well as ERK/MAPKs (Winston and Hunter, 1995). The GHR/JAK2-mediated
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activation of ERK2/MAPK is through both Ras and Raf (Winston and Hunter,
1995). GH promoted the rapid, transient association of SHC with the Grb2-SOS
complex. This correlated with the time course of Ras, Raf, and MEK activation
with Ras, Raf, and MEK returning to near basal activity by 15 or 30 min despite
the continuous presence of GH (Vanderkuur et al., 1997).

Phosphorylation of the JAK2-GHR complex, through activation of MAPK,
leads to increased IGF-1 mRNA expression in liver (Xu et al., 1995). The
GHR/JAK2-MAPK stimulation of IGF-1 production shows an age-related decline.
In 17-month-old female C57BL/6 mice IGF-1 gene expression is decreased, but
this is not directly associated with decreased GHR complex phosphorylation or
MAPK activity (Xu et al., 1995). However, by the age of 31 months the decrease
in IGF-1 gene expression is associated with a marked decline in GHR and JAK2
phosphorylation and decreased MAPK activity (Xu et al., 1995).

GH stimulation leads to phosphorylation of Elk-1 and transcriptional
activation (Hodge et al., 1998). Overexpression of dominant-negative Ras or the
ERK-specific phosphatase, mitogen-activated protein kinase phosphatase-1, or
addition of the MEK inhibitor PD098059, blocked GH-stimulated activation of
Ras/MEK/ERK pathway and abrogated GH-induced activation of Jun N-terminal
kinase and phosphorylation of Elk-1 in 3T3-F442A cells (Hodge et al., 1998). GH
also activates MAPK in a less direct manner, via tyrosine phosphorylation of the
epidermal growth factor receptor, stimulating its association with Grb2, and
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resulting in activation of the MAPK signaling pathway in liver tissue (Yamauchi et
al., 1998).

PI3- kinase pathway. GH induces tyrosine phosphorylation of insulin
receptor substrate (IRS)-1/IRS-2 in liver (Yamauchi et al., 1998). IRS-1, -2, and 3 are phosphorylated by JAK2 providing docking sites for p85 PI3-kinase and
activating PI3-kinase leading to downstream biological effects (Yamauchi et al.,
1998). Wortmannin, a specific PI3-kinase inhibitor completely, blocked the antilipolytic effect of GH in 3T3 L1 adipocytes (Yamauchi et al., 1998).

STAT pathway. GH activates JAK2 tyrosine kinase and members of the
STAT family of transcription factors, including STATs 1, 3, and 5 (Smit et al.,
1997). At least two STAT5 proteins (STAT5A and STAT5B) exist in mouse and
human (Smit et al., 1997). GH activates both STAT5A and STAT5B in several
cell types (Smit et al., 1997). GH-dependent tyrosyl phosphorylation of both
STAT5A and STAT5B requires the same specific regions of the GHR and
activation of JAK2 kinase (Smit et al., 1997). GH plays an important role in
specific gene transcription through transient activation of STAT proteins (RicoBautista et al., 2004). GH activates STAT5 by a rapid but transient mechanism
that involves tyrosine phosphorylation and nuclear translocation (Fernandez et
al., 1998). GH-induced STAT5 DNA-binding activity was detected after 2 min,
reached a maximum at 10 min, decreased rapidly up to 1 hr of GH treatment,
and the remaining activity declined slowly thereafter (Fernandez et al., 1998).
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Termination of GH signaling at the GHR/ JAK complex occurs through
GH-induced ubiquitination/internalization of the GHR and also by the action of
SOCS (suppressor of cytokine signaling) (Rico-Bautista et al., 2004). Greenhalgh
and Alexander (2004) reported that SOCS are a family of proteins that are
produced in response to signals from cytokines and growth factors and which act
to attenuate cytokine signal transduction. Members of the SOCS family (SOCS-1
to SOCS-7 and CIS) share a central SH2 domain and a C-terminal SOCS box
and form a classical negative feedback loop that inhibit JAK/STAT signalling
cascade (Larsen and Ropke, 2002). Recent studies indicated that SOCS bind to
phosphotyrosines on the target protein through their SH2 domain, leading to
inhibition of signal transduction by N-terminal inactivation of JAK resulting in
blocking of access of STAT to the receptor sites (Larsen and Ropke, 2002). In
addition, SOCS through their SOCS box-targeting bound proteins to proteasomal
degradation (Larsen and Ropke, 2002).The expression of CIS, SOCS1, SOCS2
and SOCS3 proteins is induced in cells stimulated with GH and their overexpression in cell lines blocks aspects of GH signalling (Greenhalgh and
Alexander, 2004). On the other hand, mice lacking SOCS2 display gigantism
accompanied by evidence of lack of regulation of GH signaling (Greenhalgh et
al., 2005).

GH signaling is also affected by the integrity of cellular cytoskeleton. The
GHR/JAK2/STAT5 signaling pathway is negatively regulated by the integrity of
the actin cytoskeleton network, which facilitates GHR ubiquitination and
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degradation (Rico-Bautista et al., 2004). Rico-Bautista et al. (2004) investigated
the effects of actin cytoskeleton disruption on the kinetics of GH-activated
GHR/JAK2/STAT5 signaling pathway. They found that disruption of the actinbased cytoskeleton with cytochalasin D (CytoD) prolonged both JAK2/STAT5
tyrosine phosphorylation and STAT5 DNA binding activity. In addition, they
demonstrated that although CytoD treatment did not affect the synthesis of
SOCS proteins (SOCS-1, -2, and -3), the inhibitory actions of SOCS1, 2, and -3
on GH-induced STAT5 reporter activity were partially blocked by disruption of the
cytoskeleton. They also reported that the disassembly of actin filaments by
CytoD was accompanied by accumulation of ubiquitinated forms of GHR, but it
did not affect GHR internalization.

Although GH-induced JAK2/STAT5 activation was independent of protein
synthesis, a rapid decrease in STAT5 DNA-binding activity within 1 hour is
dependent on protein synthesis (Fernandez et al., 1998). JAK2 tyrosine
phosphorylation and STAT5 DNA-binding activity were prolonged for at least 4
hours in the presence of cycloheximide, a protein synthesis inhibitor, indicating
that maintenance of desensitization requires ongoing protein synthesis
(Fernandez et al., 1998). Termination of GH-induced STAT5b signaling involves
down-regulation of JAK2 signaling to STAT5b by phosphotyrosine phosphatase
(Gebert et al., 1999).
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Cellular stress may modulate transcription through the JAK/STAT
pathway. Flores-Morales et al. (2001) reported that endoplasmic reticulum stress
prevents the inactivation of STAT5 DNA binding activity by modulating the rate of
JAK2/STAT5 dephosphorylation. They found that endoplasmic reticulum
stressors dithiothreitol, calcimycin (A23187) and 1,2-bis(o-aminophenoxy)ethaneN,N,N,N-tetraacetic acid (acetoxymethyl) ester (BAPTA-AM) prolong GH-induced
phosphorylation of JAK2 and STAT5.

STAT5 pathway versus MAPK and PI3-kinase pathways in mediating
GH action. GH induces tyrosine phosphorylation of IRS-1/IRS-2 in liver
(Yamauchi et al., 1998). IRS-1 expression augments the Ras/Raf/ MEK1
/MAPK and PI3K pathways more than the tyrosine phosphorylation of STAT5
(Liang et al., 2000). The level of GHR is rapidly reduced by short exposure to
GH, which resulted in an equal desensitization of the JAK2/STAT5 pathway and
time dependent recovery in the absence of GH (Ji et al., 2002). Unlike the
JAK2/STAT5 pathway, the activating effect of GH on the MEK/ERK and PI 3kinase/Akt pathways did not recover following prolonged incubation in the
absence of GH (Ji et al., 2002). This result indicates the presence of an
additional post-receptor mechanism causing the prolonged refractoriness of the
MEK/ERK and PI 3-kinase/Akt pathways in response to a second GH stimulation
(Ji et al., 2002). The JAK2/STAT5 signaling pathway is required for GH/PRLinduced pancreatic beta-cell proliferation; however, MAPK, PI3K, and PKC
signaling pathways are not required (Friedrichsen et al., 2001).
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Protein synthesis, synaptic plasticity, and GH
GH is well known for its ability to stimulate protein synthesis through both
transcription and translation. GH/ IGF-1/insulin/ and p38 MAPK signaling
pathways have important roles in the regulation of protein synthesis. Inhibition of
the activity of these pathways plays an important role in the reduced rate of
protein synthesis in aged rodents (Hsieh and Papaconstantinou, 2004). GHD has
well known detrimental effects on cognition and memory in humans. Memory
formation in mammals requires protein synthesis (Flexner et al., 1963; Davis and
Squire, 1984). Studies in hippocampal slice preparations have distinguished two
phases of LTP, an early phase (E-LTP) lasting for 2 hr and a late phase (L-LTP)
which is greater in amplitude and longer in duration (> 3 hr) based on the
differential sensitivities to mRNA and protein synthesis inhibitors (Nguyen et al.,
1994). Distinct temporal phases of memory and synaptic plasticity have been
delineated in rodent hippocampus with long lasting forms distinguished by their
dependence on macromolecular synthesis (Kelleher et al., 2004b). The
regulation of protein synthesis underlying long-lasting synaptic plasticity might
occur at the transcriptional or translational level (Kelleher et al., 2004b).

The effect of protein synthesis inhibition on long lasting synaptic plasticity
is a specific consequence of translational blockade and not due to non-specific
effects or toxicity (Kelleher et al., 2004b). Several observations support this
claim. First, the action of protein synthesis inhibitors is specific to long lasting
forms of synaptic plasticity with no effect on the transient forms. Second, protein
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synthesis inhibitors typically interfere with the maintenance, not the initial
induction of long lasting synaptic plasticity. Third, both L-LTP and L-LTD are
blocked by protein synthesis inhibitors (Kelleher et al., 2004b). Fourth, calcium
influx induced by depolarization or metabotropic GluR activation is not affected
by the widely used protein synthesis inhibitor, anisomycin (Linden, 1996).
Finally, several agonists such as BDNF and NT4, forskolin and memberanepermeable cAMP analog Sp-cAMP, and dopamine receptor type D1/D5 agonists
can induce the long lasting protein-dependent forms of LTP (Kang and Schuman,
1995). The L-LTP induced by all those agents differs from L-LTP induced by
repeated tetanization in that it develops gradually, requiring 1-2 hr to reach a
maximum level and is abolished completely by pretreatment with protein
synthesis inhibitors (Kelleher et al., 2004a).

In order to answer the following questions, what signaling pathway(s) are
responsible for short-term effects of GH on hippocampal synaptic function, and is
synthesis of new proteins required for these effects? I hypothesized that GHR
signaling in hippocampus would use signaling pathways previously described in
other tissues. This hypothesis was tested by examining the effects of
pharmacological inhibition of specific components of the hypothesized
hippocampal GHR signaling pathway. The following set of experiments was
conducted to assess the possible contributions of JAK2, STAT5, MAPK, and PI3kinase pathways, and protein synthesis to the GH-induced enhancement of
excitatory synaptic transmission.
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Materials and methods

The methods used for hippocampal slice preparation, field potential
recording and data analysis were as discussed in the previous section.

To examine the effect of in vitro GH treatment on the expression of GH
receptors and STAT5a/b, hippocampal slices were prepared and allowed to
recover for 1 hr before use in experiments. For each experiment, slices obtained
from the same animal were placed into 2 separate interface holding chambers.
The slices in one chamber were exposed to ACSF alone to serve as a control,
and in the other chamber slices were exposed to ACSF + 2 nM GH. For
detection of GHR mRNA, hippocampal slices were treated with GH (2 nM) or
ACSF alone for 3 hr, then collected, rapidly frozen on dry ice, and stored at
-80 °C until used for RNA isolation. For detection of total and phosphorylated
STAT5a/b, hippocampal slices were treated with GH (2 nM) or ACSF alone for
15-30 min, then were collected and rapidly frozen on dry ice, and stored at -80 °C
until used for protein analysis.

Western Blotting
Hippocampal slices were homogenized in protein lysis buffer [1% Nonidet
P-40 (NP-40), 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS),
0.15 M NaCl, 0.01 M sodium phosphate, pH 7.2, 2 mM ethylenediamine
tetraacetic acid (EDTA), and 1% protease inhibitor cocktail]. Then, burst
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sonication was done (< 10 sec), and samples were centrifuged at 14,000 × g for
20 min. at 4 °C. The supernatant solution was obtained and total protein
estimated using the Bradford method (Bradford, 1976). Equal amounts of total
protein from GH treated slices and control slices (200 µg) were separated on 8%
polyacrylamide gels. The separated proteins were transferred to nitrocellulose
membranes (Micron Separations, Inc., Westboro, MA). The membranes were
blocked (1 hr at room temperature) in 5% nonfat dry milk in T-T-S (0.5% Tween20, 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.2 mM EDTA). The membranes
were then incubated with primary antibody diluted in 5% non-fat dry milk in T-T-S
either at room temperature for 1 hr or overnight at 4 °C. Next, membranes were
then washed and incubated with horseradish peroxidase (HRP)-conjugated
secondary antibodies, diluted 1:10,000 in 5% non-fat dry milk in T-T-S (1 hr at
room temperature or 4 °C overnight). Blots were washed again and proteins
were detected on X-ray film (Fuji Medical System USA, Inc., Stamford, CT) using
the ECL system (Amersham-Pharmacia), following the manufacturer’s
instructions. To correct for possible loading differences, blots were probed with
an antibody to neuron-specific enolase (NSE). The following primary antibodies
were used: anti-NSE (AB951, Chemicon International, 1:6000 to 1:8000), antitotal STAT5 (Clone 89, Catalog Number # 610192, BD Bioscience, 1:250), antiphospho-STAT5 A/B (Y694/Y699) (mouse monoclonal IgG, clone 8-5-2; catalog
# 05-495, Upstate Biotechnology, 1:250).
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RT-PCR
Total RNA from hippocampal slices was prepared using TRI Reagent
(Sigma). cDNA was synthesized from 2.5 µg total RNA using 100µM random
hexamer as primers. The mixture was heated to 65 °C for 5 min, and quickly
chilled on ice. I added 4 µl of 5X First Strand Buffer (Invitrogen, Carlsbad, Ca),
0.02 M DTT, and 40 U of Ribonuclease Inhibitor (Invitrogen), the reaction was
placed in a PTC-100 thermal cycler and incubated at 25 °C for 10 min and then
at 37 °C for 2 min. 200 U of M-MLVRT (Invitrogen) was added, and the mixture
was incubated at 37 °C for 50 min and then at 70 °C for 15 min. For the PCR
reactions the following primers were used: GHR right 5´ (acttctgcggctgagcaaac)
3´ and GHR left 5´ (ccttggagcaaaggatgacg) 3´. The protocol for amplification
was 95 °C for 1 min, 60 °C for 30 s and 72 °C for 1 min, for 35 cycles. Using the
cDNA prepared by RT-PCR, the following reaction was prepared: 50 µl total
reaction volume; 33.5 µl of H2O, 0.5 µl of the right primer and 0.5 µl of the left
primer, 0.5 µl of taq polymerase, 6 µl of 25 µM MgCL2, 1 µl of 10 µM dNTPs, 5 µl
of 10X PCR buffer, and 2 µl of either samples or controls.

Reagents
Reagents used in this study were rhGH (Bachem); 1,4-diamino-2,3dicyano-1,4-bis(2-aminophenylthio)-butadiene (U-0126); tyrphostin AG 490 (LC
Labs); wortmanin (WORT) (Sigma); cycloheximide (3-[2-(3,5-Dimethyle-2oxocyclohexyl)-2-hydrxyethyl]glutarimide) (Sigma). The last three reagents were
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dissolved in Dimethyle sulfoxide (DMSO). Salts and other compounds were from
Sigma or Fisher.

Data analysis
Field potentials were collected and analyzed using WinWCP program
(John Dempster, University of Strathclyde). Densitometric analysis was
conducted using ImageJ (Wayne Rasband, NIMH). Additional analysis was
completed using Excel (Microsoft) and Origin (OriginLab). All statistics are
presented as mean ± one standard error of the mean. Statistical significance was
assessed using paired and unpaired t-test, as appropriate, with p<0.05
considered significant.
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Results

GH treatment of in vitro hippocampal brain slices increased the expression
of GHR message
To determine the effect of GH treatment on the expression pattern of GH
receptors, I used RT-PCR of hippocampal brain slices treated with GH (2 nM) for
3 hours GH treatment significantly increased (p< 0.002) the expression of GHR
mRNA compared to control treated with ACSF alone (Figure 10).

GH treatment of in vitro hippocampal brain slices did not alter total or
phospho-STAT5A/B proteins
To examine the effect of GH treatment on the expression pattern of total
and phospho-STAT5a,b, I used western blot analysis of hippocampal brain slices
treated with GH (2 nM) for 15-30 min. GH treatment did not affect the protein
levels of either total or phospho-STAT5a,b compared to control tissue treated
with ACSF alone (Figure 11).

GH-induced potentiation of fEPSPs was blocked by inhibitors of PI3 kinase,
MAPK kinase, and JAK2 tyrosine kinase
To investigate the role JAK2, PI3-kinase and MAPK in mediating the
effects of GH on hippocampal synaptic transmission, I pretreated (30 min),
hippocampal brain slices with tyrphostin AG 490 (10 µM) to block JAK2 protein
tyrosine kinase, wortmannin (50 nM) to block the PI3-kinase signaling pathway,
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and U0126 (20 µM) to block the MAPK pathway. GH (1 nM) was then applied.
Each of these three inhibitors significantly reduced the effect of GH on excitatory
synaptic transmission in CA1 region of rat hippocampus. These results indicate
that activation of JAK2, PI3-kinase and MAPK signaling pathways are all
important for the induction of GH effect on hippocampal synapses (Figure 12).

PI3-kinase and MAPK inhibitors had no effect on the maintenance of GH
enhanced excitatory synaptic transmission in the hippocampus
I conducted an additional experiment to determine if PI3-kinase and
MAPK signaling pathways are important for the maintained effects of GH on
hippocampal synaptic transmission. Hippocampal slices were treated with GH (1
nM) for 30 min, to allow the initial enhancement by GH of synaptic transmission,
then WORT (50 nM) or U-0126 (20 µM) were added along with GH for another
30 min. Neither WORT nor U-0126 had any effect on the maintenance of GH
enhancement of hippocampal synaptic transmission (Figure 13), suggesting that
while PI3-kinase and MAPK are required for the initiation of GH-induced
enhancement, neither is required for the maintained expression of GH-dependent
synaptic enhancement.
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Protein synthesis is required for the induction of GH enhancement of
synaptic transmission
To investigate the role of protein synthesis in the induction of GHdependent synaptic enhancement, I pretreated hippocampal brain slices with 60
µM cycloheximide for 30 min before GH (1 nM) treatment. Cycloheximide
application was maintained during GH application for 1 hour Pretreatment with 60
µM cycloheximide for 30 min completely blocked the GH effect on excitatory
synaptic transmission of rat hippocampus. This result indicates that synthesis of
new proteins is required for the induction of GH-dependent synaptic
enhancement (Figure 14).

Protein synthesis is not important for maintained expression of GH
enhancement of synaptic transmission
To determine the possible role of continued protein synthesis in the
maintained expression of GH-dependent synaptic enhancement, I applied
cycloheximide (60 µM) beginning 30 min after the start of GH (1 nM) treatment.
Cycloheximide applied 30 min after initial treatment with GH had no effect on the
maintained expression of GH enhancement of excitatory synaptic (Figure 15).
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Figure 10. GH treatment of in vitro hippocampal brain slices increased the
expression of GHR mRNA.
A. Total RNA was prepared from hippocampal brain slices treated with GH (2
nM) for 3 hr (+) and from control slices treated with ACSF alone (-). cDNA was
prepared from total RNA as described in the materials and methods. GH
treatment increased the expression of GH receptor mRNA compared to control
treated with ACSF alone. The upper panel shows GHR mRNA for GH treated
and control slices. The lower panel shows the NSE mRNA.
B. Denistometric analysis of GHR mRNA. GH treatment caused a significant
upregulation of GHR message (***p=.002). The data represent the average of 8
pairs of GH and ACSF control slices.
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Figure 11
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Figure 11. GH treatment of in vitro hippocampal brain slices did not affect
protein levels of either total or phospho-STAT5a/b.
A. Total protein was prepared from hippocampal brain slices treated with GH (2
nM) for 15-30 min (+) and from control slices treated with ACSF alone (-).
Western blot analysis was done as described in the materials and methods using
antibodies directed against either total or phospho-STAT5. Upper panel shows a
blot probed with anti-phospho-STAT5 A/B (1:250). The middle panel shows a blot
probed with anti-STAT5 (1:250). Both the upper and middle panels are from the
same hippocampal samples. The lower panel shows a blot probed with anti-NSE
(1:8000), again from the same samples. GH treatment did not affect protein
levels of either total or phospho-STAT5a/b, or NSE. B. Densitometric analysis of
total or phospho-STAT5a/b. In vitro treatment with GH (2 nM, 15-30 min) had no
significant effects on total or phospho-STAT5a/b (all p's >0.05). C. There was no
significant change in the ratio of phospho-STAT5a/b to Total STAT5a/b in GH
treated slices compared to control ACSF alone. Data shown represent the
average of 8 pairs of slices. The bars show the mean ± SE of the mean.
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Figure 12.
A
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Figure 12. GH-induced potentiation of the fEPSP was blocked by inhibition
of PI3 kinase, MAPK kinase and JAK2 tyrosine kinase.
A. Slices were pretreated for 30 min with 50 nM WORT (up-triangle, n=8), 20 µM
U0126 (circle, n=7), or 10 µM Tyrphostin AG490 (down-triangle, n=8) before the
application of GH (1 nM). The application of these inhibitors completely blocked
the normal enhancing effect of GH on excitatory synaptic transmission. In the
sample fEPSPs shown in the insets at the top, baseline responses are indicated
by thin lines and responses after GH application by thick lines.
B. Summary of effects of GH in slices pretreated with WORT, U-0126, and,
Tyrphostin AG-490. There was no change in fEPSP following GH application in
slices pretreated with WORT or U-0126 or Tyrphostin AG490 compared to
baseline (p>.05). The increase in fEPSP slope following treatment with GH alone
was significantly greater than slices pretreated with WORT, U-0126 and
Tyrphostin AG 490 (p<0.05). *p<.05 vs GH, **p<.01 vs GH.
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Figure 13.
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Figure 13. PI3-kinase and MAPK kinase inhibitors had no effect on the
maintained expression of GH enhancement of fEPSPs.
A. WORT (50 nM) or U-0126 (20 µM) was applied 30 min after the initial
application of GH (1 nM). Neither of these two inhibitors affected GH-dependent
enhancement of excitatory synaptic transmission when inhibitor treatment
followed initial GH application by 30 min. The insets at top illustrate the effects of
GH alone or GH with WORT or with U-0126 applied 30 min after beginning GH
treatment.
B. Neither WORT nor U0126 inhibited maintenance of GH-induced enhancement
of EPSPs. There was no significant difference between GH application alone or
GH followed 30 min later with WORT or U0126 (p>0.1). The increases in EPSP
slope following treatment with GH alone or GH followed by WORT or U0126
were all significant when compared with pre-GH baseline (**p<0.01, ***p<.001).
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Figure 14.
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Figure 14. Protein synthesis was required for the induction of GH
enhancement of synaptic transmission.
A. Pretreatment of hippocampal brain slices with 60 µM cycloheximide for 30 min
before GH treatment (1 nM) completely blocked the normal GH enhancement of
excitatory synaptic transmission. The insets at top show example recordings from
individual slices (N= 6).
B. Summary comparison of the effects of GH alone, GH in slices pretreated with
cycloheximide, and cycloheximide alone. There was no significant difference
between GH application in slices pretreated with cycloheximide and control
treated with ACSF or cycloheximide alone (p>0.1). GH alone caused a
significantly greater increase in EPSP slope than GH+cycloheximide (p< 0.004).
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Figure 15.
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Figure 15. Protein synthesis was not required for maintained enhancement
of EPSPs by GH.
A. The application of cycloheximide (60 µM) beginning 30 min after the start of
GH treatment (1 nM) had no effect on GH-dependent EPSP enhancement. Slices
were treated with GH alone (squares), or with cycloheximide beginning 30 min
after initial application of GH (up-triangles). Control slices were treated with
cycloheximide alone (circles). The insets at the top show fEPSPs from individual
slices, (n = 7).
B. Summary comparison of the effects of GH, GH + cycloheximide,
cycloheximide alone, and ACSF alone. There was no significant difference
between GH alone and GH followed by cycloheximide (p>0.1). The increases in
EPSP slope following treatment with either GH or GH followed by cycloheximide
were significantly greater compared to both ACSF (p<0.005) and cycloheximide
(p<0.007) controls.
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Discussion

In vitro GH treatment increased the expression of GH receptor message in
hippocampus
One of the factors that contributes to differential tissue responsiveness to
GH is tissue-specific autoregulation of GHRs and GHBPs. I used RT-PCR to
determine the effect of GH treatment on the expression of GHRs in hippocampal
brain slices treated with GH for 3 hours GH treatment increased the expression
of GHR mRNA compared to control treatment with ACSF alone (Figure 10). This
result is consistent with the previous findings of Hull and Harvey (1998), who
reported a 25-50% increase in GHR and GHBP mRNA in all brain regions of
hypophysectomized rats following a single bolus GH injection.

My results are also supported by the finding of Vikman et al. (1991) that
GHR mRNA levels increased within 1 hr of a single injection of human GH (100
µg/rat), with maximal levels being reached 3-12 hr after the injection. In the
Vikman et al. (1991) study, the increase in GHR mRNA levels was dose
dependent, and also was observed after prolonged treatment (1 or 5 mg/kg/day
for 6 days) with bovine GH. Furthermore, there was a rapid GH-dependent
upregulation of GHR mRNA in adipose tissue (Vikman et al., 1991). Also, Le
Greves et al. (2002) reported an increase in the expression of GHR gene
transcripts in young adult rats following GH treatment by s.c. injection for 10
days.
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PI3 kinase, MAPK kinase, and JAK-2 tyrosine kinase are necessary only for
the induction but not for the maintained expression of GH enhancement of
excitatory synaptic transmission
GH interacts with cell-surface GHRs resulting in activation of the GHRassociated tyrosine kinase, JAK2, and triggering signaling cascades involving
STAT, Ras/Raf/MEK1/MAPK, and IRS-1/PI3-kinase pathways (Liang et al.,
2000). To investigate the role of JAK2, PI3-kinase and MAPK in mediating the
effects of GH on hippocampal synaptic transmission, I pretreated hippocampal
brain slices with tyrphostin AG 490 to block JAK2 protein tyrosine kinase,
wortmannin to block the PI3-kinase signaling pathway, and U-0126 to block the
MAPK pathway. Pretreatment of slices for 1 hr with these inhibitors completely
blocked the normal enhancing effect of GH on excitatory synaptic transmission
(Figure12). These data indicate that activation of JAK2, PI3-kinase and MAPK
signaling pathways are required for the induction of GH effects on hippocampal
synapses.

My results are consistent with the earlier work of Argetsinger et al. (1993)
and Sotiropoulos et al. (1994), who reported that activation of GHR stimulates
JAK2 kinase and facilitates the association of GHR with JAK2 into a complex
with subsequent phosphorylation of both proteins. Many intracellular proteins are
subsequently phosphorylated in a cascade, including MAPK. Kim et al. (1998)
also reported the requirement for GHR and JAK2 activation in GH signaling.
They also found that JAK2 activation by GH triggered various pathways including
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the Ras/MAPK, STAT, and IRS/PI3-kinase systems. Yamauchi et al. (1998) also
reported that the PI3-kinase signaling pathway is important in mediating GH
effect on 3T3 L1 adipocytes. They reported that wortmannin, a specific PI3kinase inhibitor, completely blocked the anti-lipolytic effect of GH on 3T3 L1
adipocytes. Yamauchi et al. (1998) reported that GH induced tyrosine
phosphorylation of IRS-1/IRS-2 in liver, with JAK2-phosphorylated IRS-1, -2, and
-3 providing docking sites for p85 PI3-kinase and activating PI3-kinase for
downstream biological effects.

To determine if the PI3-kinase and MAPK signaling pathways are required
for the maintained expression of GH effects I treated hippocampal slices with
WORT or U0126 beginning 30 min after initiation of GH treatment. Neither
WORT nor U0126 had any inhibitory effect on already established GH
enhancement of hippocampal synaptic transmission (Figure 13), suggesting that
there is no role for PI3-kinase or MAPK in the maintenance of GH-dependent
EPSP enhancement. My findings are consistent with the observation of Opazo et
al. (2003) that PI-3 kinase is specifically involved in the induction of tetanusinduced LTP, but is not required for maintenance of LTP.

How might PI-3 kinase lead to enhanced synaptic transmission? Opazo et
al. (2003) argued that PI3-kinase leads to downstream activation of the ERK
pathway in tetanus-induced LTP. Other possibilities were suggested by Impey et
al. (1998) and Davis et al. (2000), who reported that ERK activation contributed
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to LTP induction by facilitating transcriptional events, mRNA synthesis and
protein synthesis. The effective blockade of L-LTP requires treatment with a
translational inhibitor around the time of L-LTP induction, whereas treatment after
L-LTP induction produces no effect (Otani et al., 1989; Frey and Morris, 1997).
Alltogether, there is considerable evidence that both protein synthesis and PI3kinase activation are important for the induction but not the maintenance of LTP.

Based on the roles of protein synthesis and PI3-kinase, it seems possible
that MAPK and ERK activation are also important for the induction of LTP but not
for the maintenance of LTP. Both PI3-kinase and MAPK signaling pathways are
important for LTP induced by repeated tetanization; MEK inhibitors strongly
reduce the induction of LTP by TPS (Winder et al., 1999; Watabe et al., 2000).
Furthermore, LTP induced by short trains of TPS is almost completely blocked by
the PI3-kinase inhibitors LY294002 and wortmannin (Opazo et al., 2003). The
marked similarity in pathways required for GH enhancement of excitatory
synaptic transmission and for tetanization induced L-LTP suggests that
competition within a common set of pathways may be the underlying cause of
my finding that GH pretreatment of rat hippocampal brain slices blocks
subsequent synaptic potentiation by tetanus.
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GH treatment of in vitro hippocampal brain slices does not affect total or
phospho-STAT5A/B protein levels.
GH activates JAK2 tyrosine kinase and members of the STAT family of
transcription factors, including STATs 1, 3, and 5 (Smit et al., 1997). GH plays an
important role in specific gene transcription through transient phosphorylational
activation of STAT proteins (Rico-Bautista et al., 2004). GH-induced STAT5
DNA-binding activity was detected after 2 min, reached a maximum at 10 min,
decreased rapidly with up to 1 hr of GH treatment, and declined slowly with even
longer GH treatment (Fernandez et al., 1998). At least two STAT5 proteins
(STAT5A and STAT5B) exist in mouse and human (Smit et al., 1997). GH
activates both STAT5A and STAT5B in several cell types (Smit et al., 1997).
GH-dependent tyrosyl phosphorylation of both STAT5A and STAT5B requires
the same specific regions of GHR and activation of JAK2 kinase (Smit et al.,
1997). To determine the effect of GH treatment on the expression of total and
phospho-STAT5a,b, I used western blot analysis of hippocampal brain slices
treated with GH (2 nM) for 15-30 min. GH treatment did not affect protein
expression of total or phospho-STAT5a/b compared to ACSF alone control
(Figure 11).

Although GH has well known stimulating effects on three major signaling
pathways, there is considerable variability in the level of activation of these
different pathways among different tissues, and a corresponding variability in the
importance of these three pathways in mediating specific effects of GH. For
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example, Yamauchi et al. (1998) found that GH induced tyrosine phosphorylation
of IRS-1/IRS-2 in liver, and the IRS-1 augmentation of Ras/Raf/MEK1/MAPK and
PI3K pathways was greater than the tyrosine phosphorylation of STAT5 (Liang et
al., 2000). Also, Ji et al. (2002) reported that unlike the JAK2/STAT5 pathway,
the effect of GH on activation of the MEK/ERK and PI3-kinase/Akt pathways did
not recover following prolonged incubation in the absence of GH. Finally,
Friedrichsen et al. (2001) found that JAK2/STAT5 signaling pathway was
required for GH/PRL-induced pancreatic beta-cell proliferation; however, MAPK,
PI3K, and PKC signaling pathways were not required.

I also found that GH action on excitatory synaptic transmission was
blocked by pretreatment with cycloheximide, a protein synthesis inhibitor (Figure
16). In contrast, Fernandez et al. (1998) observed that JAK2 tyrosine
phosphorylation and STAT5 DNA-binding activity were prolonged for at least 4 hr
in the presence of cycloheximide. These discrepant observations can be
explained by Gebert et al. (1999), who found that termination of GH-induced
STAT5b signaling is a complex process involving down-regulation of JAK2
signaling to STAT5b via dephosphorylation by phospho-tyrosine phosphatase.
Because JAK2/STAT5 signaling is enhanced by protein synthesis inhibitors,
whereas GH enhancement of excitatory synaptic transmission was prevented by
protein synthesis inhibition, it seems even more unlikely that JAK2/STAT5 is
required for GH effects on hippocampal excitatory synaptic transmission.
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Protein synthesis is necessary for the induction but not the maintenance of
GH enhancement of synaptic transmission
Protein synthesis in mammals is required for memory formation (Flexner
et al., 1963; Davis and Squire, 1984). Studies in hippocampal slice preparations
have distinguished two phases of LTP, an early phase (E-LTP) lasting for 2 hr
and a late phase (L-LTP) greater in amplitude and longer in duration more than 3
hr, based on different sensitivities to mRNA and protein synthesis inhibitors
(Nguyen et al., 1994). In my experiments, GH enhanced excitatory synaptic
transmission in CA1 area of rat hippocampus, and this effect lasted for more than
3 hours Because of the similar nature of the enhancement, and the similarity in
signaling pathways, we may consider the GH effect on hippocampal synapses as
a form of L-LTP. Kelleher et al. (2004a) reported the dependence on
macromolecular synthesis for long lasting forms of memory and synaptic
plasticity in rodent hippocampus that might reflect regulation at the transcriptional
or translational level. To investigate the role of protein synthesis in the induction
of GH-dependent L-LTP, I pretreated hippocampal brain slices with 60 µM
cycloheximide for 30 min before GH treatment. This pretreatment completely
blocked the normal effect of GH on excitatory synaptic transmission (Figure 14),
emphasizing the importance of protein synthesis in the induction of GHdependent L-LTP. The validity of this interpretation of my data is supported by
the finding of Kelleher et al. (2004a) who showed that the effects of protein
synthesis inhibitors on long lasting synaptic plasticity are the specific
consequence of their translational blockade.
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Several agonists can induce long-lasting protein synthesis-dependent
forms of LTP, including the neurotrophins BDNF and NT4, forskolin and the
memberane–permeable cAMP analog Sp-cAMP, and D1/D5 dopamine receptor
agonists (Kang and Schuman, 1995). It is well known that L-LTP induced by
repeated tetanization is dependent on protein synthesis. However, there are
differences between L-LTP induced by pharmacological agents and L-LTP
induced by repeated tetanization. Kelleher et al. (2004a) reported that chemically
induced L-LTP differs from tetanization induced L-LTP in that it develops
gradually, requires 1-2 hr to reach a maximum level, and is nullified completely
by pretreatment with protein synthesis inhibitors (Kelleher et al., 2004a).
To test the role of protein synthesis in the maintenance of GH-dependent
L-LTP, I applied cycloheximide beginning 30 min after initiation of GH treatment.
Cycloheximide applied 30 min after GH had no effect on the maintenance of GH
enhanced excitatory synaptic transmission (Figure 15). Studies on L-LTP have
indicated that effective inhibition requires treatment with a translational inhibitor
around the time of L-LTP induction, whereas delayed treatment after L-LTP
induction has no effect (Otani et al., 1989; Frey and Morris, 1997). Kelleher et al.
(2004a) reported that rates of protein synthesis increased rapidly following L-LTP
induction. They added that failure of translational inhibitors to affect already
established L-LTP argues against the simple requirement of ongoing protein
synthesis to maintain steady-state protein level.
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Previous studies indicate that repeated tetanization induces rapid
enhancement of protein synthesis, which is necessary for full L-LTP expression
(Kelleher et al., 2004a). Also, increased rates of protein synthesis can be
detected rapidly after L-LTP induction (Kelleher et al., 2004b). Taken together, if
both kinds of L-LTP, drug-induced and tetanization-induced, require protein
synthesis for their induction, then we might expect competitive inhibition of
tetanus-induced L-LTP by previous GH-induced L-LTP.

Figure 16. Diagrammatic illustration of the proposed signaling pathway for
GH in the hippocampus. GHR dimerization and activation of JAK2 leads to
stimulation of the MAPK pathway, stimulation of the PI-3 kinase pathway and
protein synthesis. Solid lines indicate direct effects and dashed lines indicate
indirect effects.
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How might growth hormone contribute to enhanced excitatory synaptic
transmission in rat hippocampus?
GH activates GHRs leading to receptor dimerization and activation of the
non-receptor tyrosine kinase, JAK2. JAK2 activation by GH triggers the activation
of various pathways including Pl3-kinase and the Ras/MAPK systems. Both PI3kinase and MAPK mediate GH-dependent enhancement of excitatory synaptic
transmission in rat hippocampus through phosphorylation of substrate proteins or
stimulation of protein translation. The GH activation of PI3-kinase and MAPK
pathways begins with GH-induced JAK2 phosphorylation, since GH effects on
EPSPs were blocked by the JAK2 inhibitor. In support of the requirement for
JAK2, Kim et al. (1998) found that GHR and JAK2 activation are required for GH
signaling, and Yamauchi et al. (1998) reported that activation of JAK2 by GH
binding to its receptor mediates the biological actions of GH.

Although JAK2, PI-3 kinase and MAPK are required, the specific
interactions leading from JAK2 to PI-3 kinase and MAPK are not certain. Liang
et al. (2000) reported that IRS-1 expression augments both the
Ras/Raf/MEK1/MAPK and the PI3K pathways. So there is a possibility that GH
activates JAK2, which in turn activates IRS-1, which then mediates GHdependent activation of both PI3-kinase and MAPK. To test this possibility, we
would need to be able to assay IRS activation by phosphorylation, and the causal
relationship of IRS phosphorylation with respect to both PI-3 kinase and MAPK
activation.
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The second possibility is that activated GHR-JAK2 in turn activates the
MAPK signaling pathway without a requirement for IRS or PI-3 kinase.
Yamauchi et al. (1998) reported that GH stimulates tyrosine phosphorylation of
the epidermal growth factor receptor and causes its association with Grb2,
resulting in stimulation of the MAPK signaling pathway in liver. In addition,
Vanderkuur et al. (1997) reported that GH promoted the rapid, transient
association of SHC with the Grb2-SOS complex, which correlated with the time
course of Ras, Raf, and MEK activation. In the Vanderkurr et al. (1997) study,
Ras, Raf, and MEK returned to near basal activity after 15 to 30 min despite the
continuous presence of GH. Further investigation will be required to determine
the specific pathway linking GHR-JAK2 to MAPK in the hippocampus.

Synthesis of new proteins is required for the induction of GH-dependent LLTP of excitatory synaptic transmission in rat hippocampus. This regulation could
occur at either the translational level or the transcriptional level, or both.
However, the rapid onset of GH effects favors the enhancement of translation at
the ribosomal level. This hypothesis is supported by the finding of Bodian (1965),
Autilio et al. (1968), and Morgan and Austin (1968) who reported the presence of
ribosomal assemblies in neuronal dendrites and the ability of isolated synaptic
fractions to support de novo protein synthesis. In addition, the observation of
Steward and Levy (1982) that dendritic polyribosomes preferentially localized
near postsynaptic sites, suggests that local protein synthesis may be important
for synaptic regulation.
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An important question, as yet unanswered, is how GH promotes local
protein synthesis. As a potential mechanism, I propose that GH activation of PI3kinase leads to activation of another mediator that promotes protein synthesis at
the level of translation. This proposal is supported by Chou et al (1998) and Le
Good et al. (1998), who reported that PI3-kinase stimulates PDK-1, activating
PKCζ. Further support comes from the finding that inhibition of PKCζ prevents
LTP in the hippocampal CA1 region (Ling et al., 2002). Further investigation into
GH-dependent L-LTP, for example, with PKCζ inhibitors, may help to resolve this
issue.

Although there is evidence for GH stimulation of protein synthesis via
activation of PI-3 kinase, the MAPK pathway could also link GHR activation to
protein synthesis. I propose that GH through stimulation of MAPK pathway
enhances protein synthesis at the transcription level. In favor of this possibility is
the finding of Hodge et al. (1998) that GH promotes phosphorylation of Elk-1
which in turn causes transcriptional activation. In addition, these same authors
found that overexpression of dominant-negative Ras and the ERK-specific
phosphatase (mitogen-activated protein kinase phosphatase-1), and the
application of MEK inhibitor PD098059, blocked GH-stimulated activation of
Ras/MEK/ERK pathway and abrogated the GH-induced stimulation of the
transcription factors Jun N-terminal kinase and Elk-1 in 3T3-F442A cells.
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Section III

NMDA Receptor-Mediated Effects of Growth Hormone
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Introduction

Functional roles of NMDAR subunits composition
The NMDAR is an ionotropic glutamate receptor defined by its selective
activation by the agonist N-methyl-D-aspartate. The NMDAR plays crucial roles
in synaptic plasticity and development, and also in excitotoxic injury (Grosshans
and Browning, 2001, Mallon et al., 2004). NMDARs are multimeric proteins
containing two obligatory NR1 subunits, usually paired with two NR2A or NR2B
subunits (Cull-Candy et al., 2001).

While the NR1 subunit is obligatory for channel function, the NR2
composition plays an important functional modulatory role, affecting channel
kinetics and pharmacology (Yoshimura et al., 2003). Differences in NR2 subunit
composition underlie age-dependent changes in NMDAR dependent excitatory
postsynaptic current (EPSC) kinetics and pharmacology (Flint et al., 1997). The
proportion of the cells displaying fast NMDAR EPSCs and NR2A increases
during postnatal development (Flint et al., 1997). In visual cortex, NR2 subunit
composition changes with visual experience, in addition to age, affecting
neocortical plasticity through differential subunit regulation at inhibitory and
excitatory connections (Yoshimura et al., 2003).

LTP induction depends on both NMDA receptor-mediated Ca2+ influx and
subunit-specific signaling, with the intracellular C-terminal domain of the NR2
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subunits directing signaling pathways with an age-dependent preference (Kohr et
al., 2003). LTP induction at mature CA3-to-CA1 connections results primarily
from NR2A-type signaling and NR2A-type receptors. Mutant mice lacking the
intracellular C-terminal domain (NR2A∆C/∆C) were deficient in calcium signaling
required for LTP induction (Kohr et al., 2003). In young (<14 day old), but not
mature (>42 day old) mice, NR2B-containing receptors participated in LTP
induction. Consistent with the different roles of NR2A and NR2B in immature
and adult hippocampus, CA3-to-CA1 LTP in NR2A∆C/∆C was more strongly
reduced in adult than young mice, but could be restored to wild-type levels by
repeated tetanic stimulation (Kohr et al., 2003).

NMDARs have been implicated in both LTP and LTD for many years
(Dudek and Bear, 1992; Bliss and Collingridge, 1993). The ability of NMDARs to
participate in opposite forms of synaptic plasticity may be related to the pattern of
synaptic activation required to induce LTP or LTD. These different patterns of
synaptic stimulation resulted in corresponding differences in calcium signaling.
Long trains of low frequency synaptic stimulation produce modest but prolonged
elevation of intracellular calcium ion leading to LTD via the activation of
phosphatases (Lisman, 1989). On the other hand, high frequency trains of
synaptic stimulation produce a greater rise in intracellular calcium leading to LTP
via stimulation of protein kinases (Lisman, 1989). An additional factor allowing
NMDARs to participate in multiple, opposing forms of plasticity is the NR2
subunit composition of the receptor, since activation of NMDARs can produce

91
91

either increases or decreases in synaptic efficiency depending on subunit
composition (Bliss and Schoepfer, 2004).

Ifenprodil (3 µM) and Ro25-6981 (0.5 µM), selective antagonists of the
NR2B subunit, completely blocked LTD induced by low-frequency stimulation
(Liu et al., 2004; Williams, 2001). Although LTP is more sensitive to partial block
of NMDARs by low concentration of APV, neither Ifenprodil nor Ro25-6981
affected the induction of LTP by high frequency stimuli (HFS), indicating the
selective blockade of LTD by NR2B specific antagonists ( Nishiyama et al., 2000;
Cummings et al., 1996). On the other hand, APV (0.5 µM) prevented HFSinduced LTP without affecting LFS-induced LTD (Liu et al., 2004). The selective
effect of low dose APV on LTP was explained by a requirement for NR1-NR2A
NMDARs (Liu et al., 2004), since the NR2A containing NMDARs are more
sensitive to APV blockade than NR2B containing receptors (Buller et al., 1994).
An NR2A specific antagonist NVP-AAMO77 (0.4 µM) prevented both normal LTP
induced by a single episode of HFS and saturated LTP induced by multiple
episodes of HFS, but had little effect on LFS-induced LTD (Liu et al., 2004).

The relative expression levels of NR2A and NR2B is regulated
developmentally and may allow NMDARs to play distinct roles in long-term
synaptic plasticity (Erreger et al., 2005). Recordings from outside-out patches
that contain a single active channel show that NR2A-containing receptors have a
higher probability of opening and a higher peak open probability than NR2B-
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containing receptors in response to a brief synaptic-like pulse of glutamate
(Erreger et al., 2005). At high frequency tetanic stimulation (100 Hz; >100ms),
typically used to induce LTP, the charge transfer mediated by NR1/NR2A
considerably exceeds that of NR1/NR2B (Erreger et al., 2005). In contrast,
under low frequencies simulation typically used to induce LTD (1 Hz), NR1/NR2B
makes a larger contribution to total charge transfer and therefore calcium influx
than NR1/NR2A (Erreger et al., 2005).

Additional regulatory control over NMDAR function is exerted by subunit
specific phosphorylation of NMDARs (Lau and Huganir, 1995). In particular,
tyrosine phosphorylation of NR2 subunits is thought to be important for regulating
NMDA receptor function (Lau and Huganir, 1995). Studies using immunoaffinity
chromatography of detergent extracts of rat synaptic plasma membranes on antiphosphotyrosine antibody-agarose demonstrated that the NR2A and NR2B
subunits, but not NR1 subunits, are tyrosine-phosphorylated (Lau and Huganir,
1995). The selective tyrosine phosphorylation of NR2A and NR2B, but not NR1,
was confirmed by immunoprecipitation of the NR1, NR2A, and NR2B subunits
with subunit specific antibodies followed by immunoblotting with antiphosphotyrosine antibodies (Lau and Huganir, 1995). Tyrosine phosphorylation
of glutamate receptors was specific to the NMDA receptor. No tyrosine
phosphorylation of the AMPA (GluR1-4) or kainate (GluR6/7, KA2) receptor
subunits was detected (Lau and Huganir, 1995).
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Protein kinase C (PKC) potentiates NMDA receptor function via activation
of non-receptor tyrosine kinases leading to tyrosine phosphorylation of NR2A
and/or NR2B (Grosshans and Browning, 2001). Tyrosine phosphorylation of both
NR2A and NR2B is increased following treatment of rat hippocampal CA1 minislices with 500 nM phorbol 12-myristate 13-acetate (PMA) for 15 min (Grosshans
and Browning, 2001). Phosphorylation of serine 890 on the NR1 subunit is
increased with PMA treatment for 5 min with phosphorylation returning to near
basal levels by 10 min while tyrosine phosphorylation of NR2A and NR2B was
sustained for up to 15 min (Grosshans and Browning, 2001). Phosphorylation of
NR2A, NR2B and NR1 was blocked by pretreatment with the selective PKC
inhibitor chelerythrine, with the tyrosine kinase inhibitor Lavendustin A or with the
Src family tyrosine kinase inhibitor PP2 (Grosshans and Browning, 2001).

One additional mechanism for regulating NMDAR function is proteinprotein interactions among the distinct protein components of the postsynaptic
density (PSD). The three major components of the PSD are the NMDAR, the
Ca2+/ calmodulin-dependent protein kinase II (α-CaMKII), and the postsynaptic
density protein of 95 kDa (PSD-95) (Gardoni et al., 2001). The dynamic and
reciprocal interactions of the NMDAR, α-CaMKII, and PSD-95 have an important
role in hippocampal synaptic plasticity (Gardoni et al., 2001). The association of
both native and recombinant α-CaMKII and PSD-95 depends on the C-terminal
NR2A (S1389-V1464) sequence (Gardoni et al., 2001). Activation of NMDARs,
by either pharmacological means or by LTP-inducing synaptic stimulation,
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modulated the association of α-CaMKII and PSD-95 with the NR2A C-tail
(Gardoni et al., 2001).

Correlation of GH, GluRs, MEK/ERK and Pl 3-kinase/Akt pathways
GH modulates many functions of the central nervous system, improving
memory, alertness and motivation (Fargo et al., 2002). It is well documented that
GH secretion declines slowly with age reaching 25% of the adolescent level in
very old age (Corpas et al., 1993). Magnusson et al. (2002) demonstrated a
significant drop in the protein expression of the major subunits of the NMDA
receptor occur during the aging process. They indicated that subunit alterations
may explain some of the changes that are seen in NMDA receptor functions
during aging.

Sonntag et al. (2000) studied the effects of age and chronic insulin-like
growth factor-1 (IGF-1) administration on NMDA receptor density and subtype
expression in frontal cortex, CA1, CA2/3 and the dentate gyrus of the
hippocampus of young (10 months), middle-aged (21 months) and old (30
months) male Fisher 344xBrown Norway (F1) rats. No age-related changes in
125 -

I MK-801 binding or NMDAR1 protein expression were observed in

hippocampus or frontal cortex. However, they reported a significant decrease of
NR2A and NR2B protein expression in hippocampus between 21 and 30 months
of age, and administration of IGF-1 increased expression of these receptor
subtypes.
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In addition, GH might affect the expression of NMDA receptors in a more
direct way. GH treatment by subcutaneous injection for 10 days caused up
regulation of GHRs and NR2B receptor subunits, and led to a significant increase
in the NR2B/NR2A ratio in the hippocampus of young adult rats (Le Greves et al.,
2002). Aging normally leads to decreased NR1 expression in rats. This agedependent effect was antagonized by GH treatment (Le Greves et al., 2002).
Le Greves et al. (2002) found a significant positive correlation between the level
of GHR mRNA and NR2B gene transcripts indicating a GHR-mediated effect on
the synaptic function of the NMDAR complex.

Declining GH during aging may have other consequences for the synaptic
mechanisms of memory. GH induces the activation of Raf/MEK1/MAPK and PI3kinase pathways in several different tissues (Winston and Hunter, 1995;
Vanderkuur et al., 1997; Hodge et al., 1998; Yamauchi et al., 1998; Kim et al.,
1998; Liang et al., 2000; Ji et al., 2002). NMDA receptor-dependent LTP is
inhibited by drugs that inhibit PI3-kinase and MAPK/ERK activation (Opazo et al.,
2003). Several findings indicated that the Ras signaling pathway has an
important role in NMDA receptor-dependent forms of synaptic plasticity (Opazo
et al., 2003). Hippocampal LTP is altered in mice with mutations affecting H-Ras
(Manabe et al., 2000), Ras GTPase-activating protein NF1 (neurofibromin)
(Costa et al., 2002) or SynGAP (a synaptic Ras-GTPase activating protein)
(Komiyama et al., 2002). PI3-kinase inhibitors also inhibt NMDAR mediated ERK
activation (Opazo et al., 2003).
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In addition to regulating MAPK/ERK activation, PI3-kinase may contribute
to LTP by controlling the trafficking of AMPA-type glutamate receptors. PI3kinase is involved in the trafficking and insertion of GluR1 subunits of AMPA-type
glutamate receptors (Passafaro et al., 2001), including activity-dependent
changes in AMPA receptor trafficking-insertion that are implicated in LTP
(Malinow and Malenka, 2002). Membrane insertion of GluR1-containing AMPA
receptors induced by NMDA receptor activation in cultured neurons is completely
blocked by the PI3-kinase inhibitor wortmannin (Passafaro et al., 2001).

To answer the question, whether GH effects on hippocampal synaptic
function are mediated by NMDARs or AMPARs? I used specific neurotransmitter
receptor antagonists to pharmacologically isolate NMDAR and AMPAR
components of synaptic transmission, tested GH for effect on these isolated,
components and compared the isolated NMDAR-mediated fEPSPs (fEPSPNs)
and isolated AMPAR-mediated fEPSPs (fEPSPAs) to the dual component
fEPSPs. To address the question, does short-term treatment with GH have
similar consequences on NMDAR expression as long-term, chronic treatment
with GH? I used western blotting to measure NMDA-NR1, NR2A, and NR2B
expression levels in GH treated and control rat hippocampal slices.
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Materials and Methodes

Electrophysiology
The methods used for hippocampal slice preparation, field potential
recording and data analysis were as discussed in section I. To isolate AMPARdependent responses I treated slices with the NMDAR antagonist 5-aminophosphovaleric acid (D-AP5 50 µM) for 30 min before GH application. To isolate
NMDAR-dependent responses, hippocampal slices were pretreated with 6-7dinitroquinoxalline-2-3-dione (DNQX 30 µM), a specific competitive antagonist of
AMPAR, and bicuculline methiodide (BMI 10 µM), a specific competitive
antagonist of the GABAA receptor, for 30 min before application of GH. This
pharmacological method of isolating AMPAR- and NMDAR-mediated synaptic
responses was originally described by Davies and Collingridge (1989), and has
been widely used since then.

Western Blotting
To examine the effect of GH on the expression of NMDAR subunits,
hippocampal slices were prepared as described in earlier sections and allowed to
recover for 1 hour After recovery, slices obtained from the same animal were
placed into 2 separate interface chambers. The slices in one chamber were
exposed to ACSF alone to serve as a control, and the slices in the other chamber
were exposed to ACSF + GH (2 nM). After 3 hours of treatment, both groups of
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slices were rapidly frozen on dry ice and stored at -80 °C until used for protein
isolation.
Hippocampal slices were homogenized in protein lysis buffer [1% Nonidet
P-40 (NP-40), 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS),
0.15 M NaCl, 0.01 M sodium phosphate, pH 7.2, 2 mM ethylenediamine
tetraacetic acid (EDTA), and 1% protease inhibitor cocktail]. Then, burst
sonication was done (< 10 sec), and samples were centrifuged at 14,000 × g for
20 min. at 4 °C. The supernatant solution was obtained and total protein
estimated using the Bradford method (Bradford, 1976). Equal amounts of total
protein from GH treated slices and control slices (200 µg) were separated on 8%
polyacrylamide gels. The separated proteins were transferred to nitrocellulose
membranes (Micron Separations, Inc., Westboro, MA). The membranes were
blocked (1 hour at room temperature) in 5% nonfat dry milk in T-T-S (0.5%
Tween-20, 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.2 mM EDTA), and then
incubated with primary antibody diluted in 5% non-fat dry milk in T-T-S (at room
temperature for 1 hour, or overnight at 4 °C). Membranes were then washed and
incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies,
diluted 1:5000 in 5% non-fat dry milk in T-T-S (1 hour at room temperature or 4
°C overnight). Blots were washed again and proteins were detected on X-ray
film (Fuji Medical System USA, Inc., Stamford, CT) using the ECL system
(Amersham-Pharmacia), following the manufacturer’s instructions. To correct for
possible loading differences, blots were probed with an antibody to neuronspecific enolase (NSE). The following primary antibodies were used: anti-NSE
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(AB951, Chemicon International, 1:6000 to 1:8000), anti-NMDA-R1 (60021A,
PharMingen International, 1:1000), anti-NMDA-R2A (AB1555P, Chemicon, 1:500
to 1:2000), anti-NMDA-R2B (N38120, Transduction Laboratories, 1:2000 to
1:4000).

Reagents
Reagents used in this study were recombinant human GH (rhGH)
(Bachem), ranging from 1-2 nM (22-44 ng/ml); bicuculline methiodide (BMI 10
µM), 6-7-dinitroquinoxalline-2-3-dione (DNQX 30 µM) (Tocris) and 5-aminophosphovaleric acid (D-AP5 50 µM). BMI and DNQX were dissolved in DMSO.
AP5 was dissolved in 100 mM NaOH.
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Results

GH-induced potentiation of NMDAR-mediated fEPSPs (fEPSPNs)
To determine if GH can enhance NMDAR-mediated excitatory synaptic
transmission, I isolated fEPSPNs by pretreating hippocampal slices with DNQX
(30 µM) to block AMPARs and BMI (10 µM) to block GABAA receptors (as shown
in figure 17 and 19). GH enhanced pharmacologically isolated NMDAR-mediated
excitatory synaptic transmission in CA1. To ensure that the response examined
in this experiment was actually due to NMDAR activation, I applied AP5 (50 µM),
to block NMDARs, at the end of the two hours period of GH application. AP5
blocked the previous GH enhancement, verifying that GH had acted through
NMDARs to enhance excitatory synaptic transmission.

GH-induced potentiation of AMPAR-mediated fEPSPs (fEPSPAs)
To determine if GH enhances AMPAR-mediated excitatory synaptic
transmission in the CA1 region, I pretreated hippocampal slices with AP5 (50 µM)
beginning 30 min before GH application to isolate fEPSPAs (Figure18 and 19).
GH caused significant enhancement of fEPSPAs. GH enhancement of fEPSPAs
was significantly greater than the dual component fEPSPs (when GH was
applied without AP5). This result suggests that GH can act through AMPARs in
addition to NMDARs.
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GH treatment decreased the expression of NR2B protein
NMDARs have an important role in synaptic plasticity (Grosshans and
Browning, 2001; Mallon et al., 2004). Previous studies showed that NMDAR
activation can produce either increases or decreases in synaptic efficiency
depending on the subunit composition of NMDAR (Bliss and Schoepfer, 2004). In
order to investigate the effect of GH treatment on subunit composition of
NMDARs, hippocampal brain slices were perfused in ACSF containing GH (2
nM) for 3 hours Control slices were perfused with ACSF alone for the same time
period. Western blotting of hippocampal slice homogenates revealed decreased
protein expression of NR2B, but no change in NR2A or NR1 (Figure 20).
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Figure 17. GH enhanced isolated NMDAR-mediated fEPSPs (fEPSPNs).
GH (1 nM) enhanced fEPSP in slices pretreated (beginning 30 min before GH
application) with DNQX (30 µM) to block AMPA receptors and BMI (10 µM) to
block GABAA receptors. Addition of the NMDAR competitive antagonist, AP5, at
the end of the two hours GH application period verified that the enhanced fEPSP
was mediated by NMDA receptors (see the inset top left). The inset shows the
response recorded during the pre-GH baseline period (thin solid line), the
response during 2nd hour of GH treatment (thick solid lines), and the response
after addition of AP5 (dotted line). Significant enhancement of fEPSP slope was
obtained in both GH alone (squares, n=10) and GH+DNQX (circles, n=5)
compared to baseline recording and compared to ACSF alone control
(diamonds), p<.05. There was no significant difference between application of
GH alone and GH+DNQX+ BMI, p>.05.
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Figure 18. GH enhanced isolated AMPAR-mediated fEPSPs (fEPSPAs)
GH (1 nM) enhanced fEPSP slope in slices pretreated with AP5 (50 µM,
beginning 30 min before GH application) to block NMDARs. The inset shows
fEPSPs during the 15 min baseline recording (thin lines), and fEPSPS during the
2ndh of GH treatment (thick lines) either in the presence (n=6) or absence of AP5,
(n=10). GH significantly enhanced fEPSP in the presence of AP5 (uptriangles)
compared to its absence (squares, p<.05). EPSPs slope was significantly
enhanced in both the presence and absence of AP5 compared to baseline
recording and compared to ACSF control (diamonds, p<.05).
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Figure 19. Summary comparison of effects of GH alone, GH+DNQX+BMI,
GH+AP5 and control ACSF. GH enhanced both fEPSPNs and fEPSPAs. Non
significant change between the GH enhancement of fEPSPNs and dual
component fEPSPs. GH enhancement of fEPSPAs was significantly higher than
the dual component fEPSPs. Results represent the mean ± SE during the
indicated time periods; * = significant difference at p<0.04 compared to GH
treatment alone, ns = nonsignificant compared to GH application alone at p>0.3,
+ = significant difference at p<0.02 compared to pre-GH baseline and ACSF
alone.
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Figure 20. GH decreased NR2B, but not NR1 or NR2A protein
A. Hippocampal slices were treated with 2 nM GH or ACSF alone for 3 hours.
Western blotting of slice homogenates revealed decreased NR2B protein in GH
treated tissue. NR2A and NR1 levels were unaffected by GH treatment. NSE was
used as a loading control.
B. Statistical analysis of GH effects on NMDAR subunit expression. Blots were
analyzed by densitometry, and normalized relative to control. GH caused a
significant decrease in NR2B protein (**p<0.007, n = 12), but NR1 (p<0.2, n =12)
and NR2A (p<0.2, n =12) were not altered by GH.
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Discussion

GH affects the expression of NMDARs, which are required for normal
memory function. In tetanization-induced LTP, NMDARs play an important role in
the induction of synaptic potentiation, by allowing calcium influx into postsynaptic
neurons during high frequency stimulation, and the block of NMDARs, for
example, by AP5, inhibits LTP (Bliss and Collingridge, 1993). It is well known
that LTP is triggered by calcium influx into postsynaptic neurons in the CA1 area
of the hippocampus. Although metabotropic GluRs and voltage-gated calcium
channels contribute to postsynaptic calcium increase under some circumstances,
NMDARs are the major route for calcium entry (Bliss and Collingridge, 1993). To
isolate NMDAR mediated synaptic responses and examine effects of GH, slices
were perfused with ACSF containing DNQX and BMI beginning 30 min before
and continuing during GH treatment (Figure 17). I found that GH caused an
enhancement of fEPSPNs that appeared essentially identical in amplitude and
time course with the GH-enhancement of dual component fEPSPs. Thus, the
enhancing effect of GH on fEPSPs in area CA1 is mediated in part by NMDARs.

Previous studies indicated that over activation of NMDARs before or
during tetanic train reduces the probability to generate LTP of the fEPSPAs
(Coen et al., 1989; Huang et al., 1992; Izumi et al., 1992; Neuman et al., 1987),
without preventing LTP of pharmacologically isolated fEPSPNs (Bashir et al.,
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1991; Berretta et al., 1991; Gozlan et al., 1994; Xie et al., 1992). To determine if
GH enhancement of excitatory synaptic transmission in the CA1 region of
hippocampus is also mediated by AMPARs, hippocampal slices were perfused
with ACSF containing the NMDAR blocker AP5 to isolate fEPSPAs. My results
indicate that pharmacological inhibition of NMDARs by AP5 and treatment with
GH produced enhancement of isolated fEPSPAs that is significantly greater than
dual component fEPSPs (Figure 18 and 19). This result is supported by the
finding of Aniksztejn and Ben-Ari (1995) that addition of 7-Chlorolynurenate
(7Cl¯-kyn), an antagonist of the allosteric glycine site on NMDARs, and
application of strong tetanic stimulation significantly potentiated the isolated
fEPSPAs. However, strong tetanus in the absence 7Cl¯-kyn did not affect
fEPSPAs. In the study of Aniksztejn and Ben-Ari (1995), the authors tested the
hypothesis that the expression of LTP by AMPARs and NMDARs depends on the
degree of NMDAR activation during the tetanus. They found that LTP of
fEPSPAs has a lower threshold than that of fEPSPNs. They suggested that tetani
that generate LTP of fEPSPNs have a low probability of inducing LTP of
fEPSPAs. They concluded that AMPA and NMDA components are potentiated
through two different postsynaptic processes. Aniksztejn and Ben-Ari (1995)
proposed a model representing the relative contribution of AMPARs & NMDARs
to LTP as function of degree of NMDAR activation (Figure 21).
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Figure 21. Model representing the relative contribution of AMPARs and
NMDARs to LTP as function of degree of NMDARs activation. The degree of
contribution of AMPARs to LTP depends on the the degree of NMDAR activation.
At the beginning of tetanization AMPAR contribution to the postsynaptic
response is high. However, with progressively greater NMDAR activation, the
AMPA contribution to tetanization decreases gradually until it vanishes, resulting
in the bell shaped response to tetanization (modified from Aniksztejn and BenAri, 1995).

In agreement with the results of Aniksztejn and Ben-Ari, 1995; Gozlan et
al., 1994; Huang et al., 1992; Izumi et al., 1992; Xie et al., 1992; Bashir et al.,
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1991; Berretta et al., 1991; Coen et al., 1989; Neuman et al., 1987, I suggest that
GH produces strong activation of NMDARs that inhibits the AMPAR contribution
to GH-dependent L-LTP. However, keep in mind that the GH effect was of slow
onset resulting in a gradual increase in the number of NMDARs activated.
Therefore, it is wise not to rule out the possibility of an AMPAR contribution to
fEPSP enhancement at least during the initial 30 min of GH treatment. It is
important to understand how NMDARs could exert a negative regulatory effect
on the AMPAR’s response to GH. Iwakura et al. (2001) found that NMDA
treatment of cultured hippocampal neurons reduced the total number of bound
AMPARs on the neuronal surface, but not in the total membrane fraction. They
also observed that NMDA-treatment caused down-regulation of AMPA-stimulated
channel activity and reduced immunoreactivity for GluR1. They concluded that
NMDAR activation induced down-regulation of functional AMPARs. Further
investigation is needed to clarify the mechanism by which GH-induced NMDAR
activation limits the response of AMPARs.

NMDAR antagonists block the induction of both LTP and LTD (Bliss and
Collingridge, 1993; Dudec and Bear, 1992), and the NMDAR subunit composition
is considered a determining factor for LTP or LTD (Bliss and Schoepfer, 2004;
Liu et al., 2004). To investigate the role of NMDAR subunit composition in
mediating GH effects, hippocampal brain slices were perfused with ACSF
containing GH (2 nM) for 3 hours Western blots of GH treated slices showed
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decreased protein expression of the NR2B subunit of NMDARs (Figure 20).
NR2A and NR1 protein level were unaffected by GH treatment for 3 hours.

Liu et al. (2004) reported the requirement of NMDARs that is lacking their
NR2B subunits for LTP induction. The use of the NR2A specific antagonist NVPAAMO77 (0.4 µM) prevented both normal LTP induced by a single episode of
HFS and saturated LTP induced by multiple episodes of HFS, but had little effect
on LFS-induced LTD (Liu et al., 2004). Mallon et al. (2004) reported that “LTP
induction critically involves primarily receptors containing the NR2A subunit”.
They added that “endogenous factors or drugs that modify this NR2B/NR2A
interaction could have a major influence on synaptic transmission and plasticity in
the brain”. At both presynaptic and postsynaptic sites in the rat hippocampus,
NR2B-subunit-containing receptors limit NMDAR function by inhibitory restraint
over NR2A-subunit-containing receptors, via calcineurin activation (Mallon et al.,
2004).

In my experiments, GH decreased the expression of NR2B subunits but
not the NR2A subunits. According to the findings of Mallon et al. (2004), Liu et al.
(2004), Bliss and Schoepfer (2004), Bliss and Collingridge (1993), and Dudec
and Bear (1992), this decrease in the NR2B subunit should allow enhanced
function of the NR2A-containing NMDARs.The relative loss of NR2B compared
to NR2A after GH treatment might therefore contribute to the GH-induced
enhancement of fEPSPs.
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Figure 22. Diagrammatic illustration of the proposed mechanism of
interaction between GH, PI3-kinase, MAPK, and NMDARs. GH activates
GHR/JAK2, which activates PI3-kinase. PI3-kinase activates Fyn tyrosine kinase,
which then activates NMDARs. NMDARs activate SynGAP, converting inactive
ras to active ras and activating MAPK pathway.

Proposed mechanisms of interaction between GH, PI3-kinase, MAPK, and
NMDARs
My results indicate that GH-induced L-LTP was mediated at least in part
by NMDARs. Also GH treatment for 3 hours decreased expression of the NR2B
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subunit, supporting my earlier finding that GH enhanced fEPSPNs. An important
question here is: How does GH regulate NMDAR subunit expression and
NMDAR function? In addition, my finding that PI3-kinase and MAPK were
important for the induction of GH effects on fEPSPs raises another question, how
GH-induced enhancement of NMDAR function is related to PI3-kinase and
MAPK signaling pathways?

Recent studies have shown that the regulatory subunit of PI3-kinase, P85,
binds directly to NR2B subunits (Hisatsune et al., 1999). Also PI3-kinase
stimulates a group of tyrosine kinases called Fyn tyrosine kinase (Hisatsune et
al., 1999). MEK and ERK are regulated by SynGAP, a Ras GTPase-activating
protein that binds PSD-95 (Kim et al., 1998). More recent studies show that
NMDARs join large multiprotein complexes that contain a number of proteins
involved in Ras signaling (Husi et al., 2000). Taken together, These results
suggest that GH activation of the JAK2/PI3-kinase pathway enhances NMDAR
activation probably by phosphorylation, and also contributes to down-regulation
of NR2B subunits allowing NR2A to become dominant mediating GH-dependent
L-LTP (Figure 22). In addition, GH might also activate the MAPK pathway
through the association of NMDARs, PSD-95 and SynGAP. Further investigation
is needed to know the exact molecular mechanisms that link GH stimulation of
PI3-kinase and MAPK to NMDARs.
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CONCLUSION
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Previous studies have shown that GH affects many functions of the central
nervous system, with beneficial effects on memory, alertness and motivation.
Others indicated that a common set of cellular mechanisms link GH-induced
improvement of memory function to NMDARs and LTP. Yet the mechanisms by
which GH improves memory function of the brain or how GH-induced
improvement of memory function relates to NMDARs and LTP are not well
established. The purpose of this study was three-fold. First, to determine if the
short term treatment with GH affects synaptic transmission in CA1 area of rat
hippocampus. Second, if GH does affect synaptic transmission, to determine
which GH-signaling pathway or pathways are required, and to determine whether
protein synthesis is required. Third, to determine the roles of AMPARs and
NMDARs in mediating GH action.

In summary, my results showed that GH caused a long-lasting
enhancement of excitatory synaptic transmission in area CA1 of rat
hippocampus. This GH-induced L-LTP blocked further potentiation by tetanus.
GH did not act through an increase in probability of glutamate release from
presynaptic terminals. The GH-induced potentiation of fEPSPs required JAK2,
PI3-kinase, and MAPK, and the synthesis of new protein, but only during
induction of potentiation, and not during maintenance of potentiation. GH-induced
potentiation of excitatory synaptic transmission was mediated through NMDARs.
Finally, GH treatment of hippocampal brain slices increased GHR message and
decreased the abundance of NR2B protein.
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My results demonstrate that GH induced L-LTP is related to both
NMDARs channel activity and subunit composition, and there are common
signaling pathways underlying GH-induced L-LTP and tetanization-induced LLTP. Thus, GH enhancement of synaptic transmission in the hippocampus might
explain the well known finding that GH treatment improves cognition and
memory. My discovery that GH is a potent short-term modulator of excitatory
synaptic transmission in the hippocampus will facilitate a deeper understanding
of neuroendocrine regulation of memory function. However, this discovery raises
new issues that were not apparent previously. Future studies will be needed in
several areas. First, to verify the exact molecular mechanisms by which GH
induces activation of GHR/JAK2, PI3-kinase and MAPK, and alters NMDAR
expression and protein synthesis. Second, to determine whether GH stimulates
IGF-I release and to assess whether IGF-I participates in the short term effects of
GH in hippocampus.
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